Medicare & Medicaid Actionable Updates, week ending October 3, 2026

CMS reports $1.6 billion in Medicare laboratory program integrity actions across revocations, suspensions, recoupments and referrals

What changed

CMS's October 1, 2026 MLN guidance reminds providers that Medicare does not pay for duplicate laboratory tests unless medically necessary. When combining panels and individual tests, ordering and billing teams should check for duplicated components. Medically necessary repeat clinical diagnostic tests use modifier 91. This is a focused billing reminder, distinct from CMS's August 28 program-integrity announcement covering laboratory revocations, suspensions, recoupments and referrals; it does not establish a new blanket denial of every repeated test.

The August announcement's more-than-$1.6 billion total comprises $732 million in savings from 157 provider revocations, over $500 million halted through 185 suspensions during investigations of 600 labs, over $276 million recouped from 442 overpayments and $127 million prevented through 85 law-enforcement referrals. These combine savings, held payments and recovered funds, rather than one amount of adjudicated fraud or cash recovery. CMS describes analytics targeting unusual billing, services not rendered, upcoding and unnecessary testing, including pathogen, high-complexity drug and genetic tests. In the Texas examples, claims denial and suspension followed suspicious billing patterns within months. The release reports CMS's actions and suspicions, not a judicial finding against every reviewed laboratory.

Why it matters

Duplicate-test controls and trend monitoring address different risks. The aggregate illustrates tools CMS used; it does not itself impose a twelve-month internal audit or prove every reviewed claim fraudulent.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Compliance, Revenue Cycle, Coding, Clinical Operations, Provider Enrollment, Finance, Legal

What to do nextAs a self-directed review, sample duplicate panels and medically necessary repeats, review laboratory volume changes and supporting orders and medical necessity, and confirm enrollment ownership and escalation for payment notices. Treat playbook dates as internal targets.

1. Pull twelve months of laboratory claims in pathogen detection, high complexity drug testing and genetic testing, and chart the monthly volume and dollar trend by billing identifier. Revenue Cycle · due Sep 13, 2026
2. Sample the highest volume test codes and confirm an ordering provider relationship, a signed order, and a medical necessity record for each sampled claim. Compliance · due Sep 27, 2026
3. Inventory every Medicare laboratory billing identifier the organization controls or manages, including joint ventures and managed arrangements, and confirm enrollment data and revalidation ownership. Provider Enrollment · due Sep 27, 2026
4. Confirm the process for receiving and escalating a Medicare payment suspension or revocation notice, including who is notified within one business day and who leads the corrective response. Compliance · due Oct 4, 2026
5. Report the volume trend, the sample error rate, and the enrollment inventory to the compliance committee with a recommendation on prepayment self monitoring. Compliance · due Oct 18, 2026

Permalink: #cms-medicare-laboratory-payment-integrity-actions · Development ID GC-2026-0009

CMS revises the October NCD coding update and moves stem-cell changes to April 2027

What changed

CMS issued Transmittal 13968 on September 24, replacing its August 14 transmittal for Change Request 14464. The revision removes the NCD 110.23 stem-cell business requirements from the October package and says they will be included in an April 2027 change request. The rest of the quarterly NCD coding maintenance remains, with an overall October 1 effective date and October 5 implementation date unless a requirement specifies otherwise. CMS explicitly states that this request changes coding and system edits, not the underlying national coverage policy.

The retained instructions address PET cardiac perfusion edits, diagnostic bone-density codes, implantable cardioverter-defibrillator procedures, antiemetic drug coding, CAR-T therapy and a next-generation sequencing test. Several requirements carry earlier code-specific effective dates, so treating every change as applying only to October services would miss part of the package. The bone-density additions are for diagnostic indications, not monitoring. CMS directs contractors to adjust claims brought to their attention without conducting a general search for claims. The implementation task is therefore to use the revised package and its individual dates, while excluding the deferred stem-cell requirements.

Why it matters

Claims edits and coding tables need the revised scope so organizations do not implement withdrawn stem-cell changes with the October release.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Coding, IT, Compliance

First seen

Sep 27, 2026

Last materially changed

Sep 27, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextConfirm the revised file set, remove NCD 110.23 changes from the October deployment, test affected claims, and verify production implementation.

1. Confirm the revised CR 14464 file set and scope. Coding · due Sep 29, 2026
2. Remove NCD 110.23 stem-cell changes from the October deployment. IT · due Sep 30, 2026
3. Test affected claims and verify production implementation. Revenue Cycle · due Oct 5, 2026

Permalink: #cms-cr14464-october-ncd-coding-update · Development ID GC-2026-0133

Noridian posts MolDX billing-article revisions for October 1

What changed

Noridian posted five relevant JE MolDX article revisions on September 24. The notices cover myeloid next-generation sequencing A57891 R14, hereditary transthyretin amyloidosis A59872 R3, heritable thoracic aortic disease A59868 R3, cardiovascular-risk biomarkers A57037 R9 and metabolic steatotic liver disease/steatohepatitis biomarkers A60217 R1. Their October 1 changes include diagnosis-code additions or replacements, such as M04.3 for the myeloid article, Q87.A for the aortic article and K74.0A for the liver article. As of October 4, those October 1 portions are effective and should be checked against actual services and diagnosis documentation.

The notices do not give every change the same start date. The myeloid notice also adds genomic sequencing code entries and a warning that inclusion does not imply coverage, with that portion effective May 17, 2020. The amyloidosis notice includes cardiomyopathy code additions effective September 25, 2025 alongside October 2026 replacements and registry wording. A57891’s actual article directs use of the applicable code, unit and DEX identifier and points to the coverage policy and evaluated-test registry. Article maintenance therefore requires version-specific comparison rather than assuming every listed code creates coverage or a new October-only benefit.

Why it matters

Laboratory edits must apply the correct revision and effective date while preserving the distinction between coding inclusion, evaluated tests and clinical coverage.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal, California

Primary owner

Revenue Cycle

Affected functions

Clinical Operations, Revenue Cycle, Coding, Compliance

First seen

Sep 27, 2026

Last materially changed

Sep 27, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextVerify the five applicable revisions in production, compare diagnosis and DEX documentation with ordered tests, and investigate October claims using each change’s actual effective date.

1. Identify every revised MolDX article tied to tests currently ordered or billed. Clinical Operations · due Sep 28, 2026
2. Update applicable coding, documentation, and claim edits. Coding · due Sep 30, 2026
3. Verify October 1 production readiness. Revenue Cycle · due Oct 1, 2026

Permalink: #noridian-moldx-article-revisions-october-2026 · Development ID GC-2026-0134

Hospice election addendum is mandatory for every new election starting October 1

What changed

CMS’s October 1 MLN Connects explains changes made in the FY 2027 Hospice Prospective Payment System final rule. The election-statement addendum is mandatory for every hospice election starting on or after October 1, rather than only when a beneficiary asks for one. It must be furnished in writing, on paper or electronically, to the beneficiary or representative within five calendar days of the election’s effective date. CMS says it must contain the information required by 42 CFR 418.24(c), making the content of the document as relevant as whether a form was generated.

When the plan of care changes, an updated addendum must be furnished within three calendar days. The newsletter states that the payment condition is satisfied when the hospice medical record contains a valid signed addendum. To support the transition, CMS will use enforcement discretion from October 1 through December 31: contractors will not deny a claim solely because the addendum is absent or incomplete and will emphasize education. The same notice nevertheless requires hospices to furnish it to every electing beneficiary during those months. That distinction preserves the delivery and recordkeeping duties while explaining the limited temporary claims treatment.

Why it matters

Election documentation affects payment and patient understanding of excluded services. The temporary non-denial policy is a transition allowance, not an optional addendum.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Compliance, Revenue Cycle

What to do nextValidate October elections, delivery dates, signatures, excluded-service explanations and the three-day update workflow. Correct omissions promptly.

1. Validate October elections, delivery dates, signatures, excluded-service explanations and the three-day update workflow. Correct omissions promptly. Clinical Operations · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #hospice-election-addendum-is-mandatory-for-every-new-election-starting-october-1 · Development ID GC-2026-0140

Medi-Cal youth gender-affirming services: October 13 reimbursement and continuity requirements

What changed

DHCS issued All Plan Letter 26-018 on September 30 to implement the federal Medicaid and CHIP funding limitation scheduled for October 13. For service dates from then onward, it identifies specified gender-affirming surgeries, puberty blockers, hormone therapy and associated professional services that Medi-Cal managed care plans will no longer reimburse for affected Medi-Cal members under 18 and CHIP members under 19. Members already taking gender-affirming hormones as of October 13 have a transition through April 12, 2027; the plan’s responsibility is for the medical benefit. That exception does not extend to new hormone starts, puberty blockers or surgery.

Coverage continues for medically necessary treatment of other conditions, complications and services outside the listed categories, including office visits, laboratory tests, speech therapy and psychotherapy. Earlier service dates and Medi-Cal adults remain outside this change. Plans must help coordinate state-only HCAI funding, and the letter says providers should not cancel services or redirect members in the interim. It requires the approved handbook errata and, for affected prior authorizations, individualized adverse-action notices with the applicable ten-day timing, exceptions and appeal rights. Plans must update policies and submit them with the required confirmation within 90 days of the letter’s release.

Why it matters

Claims edits must preserve exceptions and continuity of care. This is not a blanket exclusion of gender-affirming or ancillary care.

Response type

Escalate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California, Federal

Primary owner

Managed Care

Affected functions

Managed Care, Clinical Operations, Case Management, Revenue Cycle, Legal

What to do nextReview affected authorizations and notices immediately. Use the approved handbook errata; assess ten-day individualized notice rules and appeal rights. Coordinate HCAI funding. Update and submit policies within 90 days of September 30.

1. Assess affected services, exceptions, notices and continuity with Legal now. Managed Care · due Oct 5, 2026
2. Validate claims and coordinate HCAI funding without cancelling care. Revenue Cycle · due Oct 13, 2026
3. Submit revised policies and required confirmation within 90 days of release. Managed Care · due Dec 29, 2026

Permalink: #medi-cal-youth-gender-affirming-services-october-13-reimbursement-and-continuity-requirements · Development ID GC-2026-0141

OIG finds $72 million in MA and Part D payments tied to excluded or felony-convicted providers

What changed

An HHS OIG data brief issued September 28 and posted October 1 examines vulnerabilities in CMS’s provider-preclusion process. OIG reviewed 1,017 National Provider Identifiers associated with providers revoked from Medicare Parts A and B but absent from the Preclusion List during 2022 and 2023. It identified $72 million in Part C and Part D payments for services associated with 249 of those NPIs during 2022 through 2024. The Preclusion List concerns payments under Medicare Advantage and Part D; it is not simply another name for every Medicare enrollment or exclusion record.

OIG identifies delays and errors in adding or removing providers, organizations not listed when their owners were excluded or had specified felony convictions, and the regulatory treatment of pharmacies that fill prescriptions without prescribing. Those dispensing-only pharmacies were not subject to preclusion under the regulations described in the brief. The agency presents these as process vulnerabilities that may inform future regulations and guidance, and makes no specific recommendations to CMS. The figures do not establish that each associated claim was fraudulent or that CMS has ordered recovery of the entire amount. Operational follow-up must distinguish enrollment revocation, exclusion, preclusion and the facts of particular payments.

Why it matters

A single screening list may miss material provider-status changes. MA, Part D, delegated networks and payment vendors need coordinated enrollment and exclusion controls.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Provider Enrollment

Affected functions

Provider Enrollment, Managed Care, Compliance, Revenue Cycle

What to do nextReconcile relevant provider status across enrollment, exclusion and preclusion sources. Investigate discrepancies, document the payment analysis and escalate repayment questions without treating the report as a blanket recoupment order.

1. Reconcile relevant provider status across enrollment, exclusion and preclusion sources. Investigate discrepancies, document the payment analysis and escalate repayment questions without treating the report as a blanket recoupment order. Provider Enrollment · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #oig-finds-72-million-in-ma-and-part-d-payments-tied-to-excluded-or-felony-convicted-providers · Development ID GC-2026-0142

Noridian finalizes two MolDX coverage policies for California effective October 12 and retires the thrombophilia policy October 11

What changed

Noridian's August 27, 2026 Jurisdiction E notices finalize two MolDX local coverage determinations for October 12: L40242 for hereditary thrombophilia and L40222 for non-next-generation-sequencing targeted molecular panels used for targeted cancer therapy. The corresponding billing articles are A60272 and A60239, with response-to-comment articles A60468 and A60509. The notices identify the covered contractor jurisdictions, including California, Hawaii, Nevada and Pacific territories. As of this October 4 edition, the finalized policies' effective date remained in the coming week.

A separate notice retires L36155, covering hypercoagulability and thrombophilia testing including Factor V Leiden, Factor II prothrombin and MTHFR, effective October 11 because L40242 supersedes it. That retirement date is distinct from the October 12 replacement date. These announcements identify which documents change and when; they do not say that every test in either family becomes noncovered. Laboratories and ordering services need the actual finalized indications and billing articles before mapping their test menus, date-of-service edits and beneficiary-notice decisions. An order date alone should not be treated as the coverage-effective date of a billed service.

Why it matters

Consecutive retirement and replacement dates require coordinated policy and coding maintenance, without assuming universal noncoverage for a test family.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal, California, Hawaii, Nevada

Primary owner

Coding

Affected functions

Coding, Revenue Cycle, Clinical Operations, Compliance, Utilization Management, HIM/CDI

First seen

Aug 30, 2026

Last materially changed

Aug 30, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextRead the named LCDs and articles, map applicable test menus and screening edits by date of service, and prepare beneficiary-notice decisions where indicated. Validate the transition before October 12.

1. Obtain L40242, L40222 and billing and coding articles A60272 and A60239, and record the covered indications and coding requirements for each. Coding · due Sep 11, 2026
2. Map the current thrombophilia and non next generation sequencing targeted panel test menu, in house and send out, against the finalized indications and list every test that loses or changes coverage. Clinical Operations · due Sep 25, 2026
3. Update the laboratory compendium, order sets, and medical necessity screening logic so the change takes effect on October 12, 2026 and the retired L36155 basis stops applying on October 11, 2026. IT · due Oct 5, 2026
4. Decide and document the advance beneficiary notice position for tests that become non covered, and brief the ordering services in writing. Revenue Cycle · due Oct 9, 2026
5. Audit a sample of thrombophilia and targeted panel claims in the first four weeks after the effective date and report the denial rate. Compliance · due Nov 13, 2026

Permalink: #noridian-moldx-lcd-finalization-jurisdiction-e · Development ID GC-2026-0011

CMS proposes a new annual Acute Hospital Care at Home reporting requirement, comments close October 26

What changed

CMS's August 27, 2026 Federal Register notice proposes a new Acute Hospital Care at Home Quantity, Intensity and Mix of Services collection, CMS-10971. It identifies annual reporting and seeks comments by October 26 on necessity, usefulness, burden estimates and ways to improve or automate collection. The notice estimates 365 respondents,13,000 annual responses and 13,000 hours. These are CMS's proposal estimates, not proof that a reporting obligation has already become operative or that every hospital must submit this tool now.

Section 6210(c) of the Consolidated Appropriations Act,2026 directs CMS to evaluate care in the hospital-at-home initiative. The proposed tool would describe services such as clinician visits, food and pharmacy services for patients admitted from emergency departments or transferred from inpatient units, supporting a report to Congress. Hospitals participate through individual CMS Certification Number waivers. The notice says CMS is seeking OMB approval; participating programs can assess whether existing documentation supplies the proposed counts and identify burden concerns during the comment period without treating the proposal as final implementation instructions.

Why it matters

Data ownership and burden can be assessed during the comment period, but a proposed collection is distinct from a currently operative annual submission requirement.

Response type

Comment

Confidence

High

Who this affects

Health systems

Jurisdiction

Federal

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Compliance, Quality, HIM/CDI, Finance, Case Management

First seen

Aug 30, 2026

Last materially changed

Aug 30, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextConfirm participation, assess availability of the proposed service counts and identify data owners. Decide whether to comment on the collection and burden by October 26, while tracking approval and final instructions.

Permalink: #cms-acute-hospital-care-at-home-qims-data-collection · Development ID GC-2026-0010

Medi-Cal requires quarterly validation of the public fee for service provider directory beginning October 1, 2026, with Provider Portal Transaction Center access at stake

What changed

The Medi-Cal directory-validation process described in DHCS's August 26, 2026 notice began October 1. Provider Portal administrators must answer all Public Fee-For-Service Provider Directory survey questions within 45 days and update or validate the information within 45 days in each later quarter. They must identify whether each organization service location accepts new fee-for-service patients, managed-care patients or both, then save the directory. The notice states the opening date and 45-day period without supplying a calendar end date; October 1 is the start of the window, not the final submission deadline.

Failure to complete the quarterly updates results in every user in the organization losing Provider Portal Transaction Center access. Affected users should contact their administrator to update the directory and restore access; the Telephone Service Center supports portal-access issues and Provider Enrollment handles other directory questions. DHCS's October 1 Notice of Change points providers to course PP401PNC through the Medi-Cal Learning Portal, requiring registration and a user profile to view it. The training notice supports the existing directory process; it does not replace the actual required survey submission or prove that an organization completed it.

Why it matters

A missed directory update can interrupt organization-wide portal transactions. Recurring ownership and accurate service-location data are therefore operational controls, not merely a contact-list exercise.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Provider Enrollment

Affected functions

Provider Enrollment, Revenue Cycle, Compliance, IT, Patient Access

First seen

Aug 30, 2026

Last materially changed

Aug 30, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextAssign a primary and backup administrator, verify service-location acceptance information, complete and save the survey within the stated window and retain confirmation. Calendar later quarterly validation and the access-restoration escalation path.

1. Inventory every Medi-Cal Provider Portal organization identifier the organization holds and identify the current administrator for each. Provider Enrollment · due Sep 18, 2026
2. Name a primary and a backup administrator per organization identifier and confirm both can reach the Provider Portal Directory survey. Provider Enrollment · due Sep 25, 2026
3. Confirm with patient access and the service line owners, per service location, whether the location is accepting new fee for service patients, managed care patients, or neither. Patient Access · due Oct 9, 2026
4. Complete and save the first directory validation inside the window that opens October 1, 2026, and record the submission date. This target date sits well inside the 45 day window rather than at its end. Provider Enrollment · due Oct 31, 2026
5. Put the validation on a recurring quarterly calendar with the named owners, and confirm the escalation path if Provider Portal Transaction Center access is lost. Revenue Cycle · due Nov 13, 2026

Permalink: #medi-cal-public-fee-for-service-provider-directory-quarterly-validation · Development ID GC-2026-0015

California challenges Medicaid and CHIP funding restrictions scheduled for October 13

What changed

California announced September 2, 2026 that a coalition of 21 attorneys general and Pennsylvania's governor sued to block the final Medicaid and CHIP reimbursement restrictions scheduled for October 13. The complaint asks the District of Massachusetts to declare the rule unlawful and prevent implementation. The AG's legal arguments are the coalition's position, not a court ruling. The August 13 final rule addresses Medicaid beneficiaries under 18 and separate CHIP beneficiaries under 19. Filing this lawsuit alone does not suspend its effective date, and these sources do not establish a later order resolving this challenge.

The operative rule limits federal matching and payment under the relevant state plans for the defined pharmaceutical and surgical interventions. It allows federal matching for a tapering period of hormone therapy of up to six months for beneficiaries receiving that therapy on October 13. Its definition excludes specified treatment of medically verifiable disorders of sexual development, interventions for other purposes and treatment of complications. It does not prohibit delivery of care or state-only/private funding outside the federally matched programs. Payment planning therefore needs the actual service, age, funding source, transition condition, California instructions and applicable court orders, rather than treating every gender-affirming service as prohibited.

Why it matters

Legal authority, federal matching, state payment direction and continuity-of-care obligations need separate verification before operating instructions change.

Response type

Assess

Confidence

Moderate

Who this affects

Health systems, Provider networks

Jurisdiction

Federal, California

Primary owner

Legal

Affected functions

Legal, Managed Care, Revenue Cycle, Clinical Operations

First seen

Sep 6, 2026

Last materially changed

Sep 6, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextVerify the docket and applicable DHCS instructions, map affected services and funding streams, and prepare contingent billing and continuity workflows. Do not change care solely because the lawsuit was announced.

1. Verify court orders and current DHCS payment direction before issuing operating instructions. Legal
2. Identify affected claims and continuity-of-care workflows by funding source. Managed Care
3. Prepare billing changes contingent on operative legal requirements. Revenue Cycle

Permalink: #medicaid-chip-gender-affirming-care-litigation · Development ID GC-2026-0022

OIG identifies $587.7 million in Part D payments involving obsolete prescription labeling

What changed

An OIG audit issued August 31 and posted September 2, 2026 found $587.7 million in ineligible Part D payments for five drugs during 2021–2023. Sponsors continued paying more than a year after the corresponding brand-name products switched to over-the-counter use, while generic products retained obsolete prescription-only labeling. Part D does not cover products that can be purchased without a prescription. The audit concerns the five identified drugs and period; the amount is an audit finding, not a newly imposed sponsor fine or a report of money already recovered.

OIG identified two oversight gaps: CMS's formulary reference file relied on obsolete FDA prescription-status data, and CMS had not set a timeframe for sponsors to reject these payments after an Rx-to-OTC switch. OIG recommended CMS issue such timeframe guidance, and CMS concurred. The report also describes FDA's December 2025 manufacturer policy requiring labeling updates as early as possible and within six months of the brand switch. That manufacturer-labeling period is distinct from the sponsor-rejection guidance OIG recommended; the audit does not itself create a universal six-month Part D rejection deadline.

Why it matters

Drug-status reference data can lag regulatory changes. Manufacturer labeling duties and sponsor claim-eligibility instructions require separate monitoring.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Managed Care

Affected functions

Managed Care, Compliance, Revenue Cycle

First seen

Sep 6, 2026

Last materially changed

Sep 6, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextAssess Rx-to-OTC monitoring, formulary/reference-file updates and affected claims with pharmacy, managed-care and legal owners. Track implementing CMS guidance before assuming a new universal rejection period.

Permalink: #oig-partd-otc-labeling-payments · Development ID GC-2026-0023

OIG flags organ acquisition reimbursement and documentation risks

What changed

OIG's organ-acquisition audit, issued September 1 and posted September 3, 2026, reviewed costs reported for 2017–2022. Of 180 sampled organs reported as Medicare usable,43 were not used in Medicare-covered transplants and 12 were never transplanted. Medicare reimbursed $2.8 million for those 55 organs. OIG estimated about $380 million across the six-year period and identified a conflict between CMS guidance and the statutory limit on reimbursement for organs used in Medicare-covered transplants. The estimate does not assign an organization-specific liability or direct blanket recovery of $380 million.

The guidance assumed that organs removed and furnished to an organ-procurement organization or another transplant center would be used for a Medicare transplant, which did not always occur. Separately, two centers lacked documentation for five reported organs, producing $154,210 in unallowable reimbursement. OIG recommended MAC recovery of that amount and revision of the organ-counting guidance to align with the statute. CMS concurred with recovery, but did not specifically concur or nonconcur with the guidance recommendation. Documentation recovery and the broader policy conflict are therefore distinct findings requiring different follow-up.

Why it matters

Organ disposition and supporting records need to reconcile to cost-report counts, while guidance conflicts require legal and MAC review rather than an assumed blanket recoupment.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Finance

Affected functions

Finance, Clinical Operations, Compliance, Legal

First seen

Sep 6, 2026

Last materially changed

Sep 6, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextTrace organ counts to disposition and documentation, assess the guidance conflict with counsel and monitor MAC instructions. Evaluate actual organization-specific exposure before treating the estimate as a payable balance.

Permalink: #oig-organ-acquisition-cost-reimbursement · Development ID GC-2026-0024

Medi-Cal fee-for-service hospices must use the new attestation portal within five days of election

What changed

DHCS's September 1, 2026 provider notice requires licensed and certified hospice providers to submit a Medi-Cal Hospice Attestation through the Provider Portal after counseling fee-for-service members, obtaining informed consent and securing a signed DHCS 8052 election notice. The portal attestation is the official notice to DHCS and must be submitted within five calendar days of the member electing hospice. This is the fee-for-service workflow described in the dated notice, rather than a new October requirement created by the later portal reminders.

The signed DHCS 8052 is not submitted to DHCS through this process. The hospice must retain it in the member's medical record and make it available on request or for a state or federal audit. The dated article points to a step-by-step portal user guide and hospice support, separating electronic notice from the underlying signed election evidence. The portal submission therefore does not replace counseling, informed consent or record retention. Admission and billing teams need to reconcile elections with submission confirmations and promptly escalate access or timeliness problems.

Why it matters

Electronic submission and signed consent serve different purposes. Missing one cannot be cured merely by possessing the other, and the five-calendar-day clock requires an assigned owner.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Revenue Cycle, Provider Enrollment, IT, Compliance

First seen

Sep 6, 2026

Last materially changed

Sep 6, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextConfirm portal access for each relevant hospice provider record. Reconcile FFS elections since September 1 to timely confirmations, retain signedDHCS 8052 and escalate missed submissions or access problems to DHCS.

1. Confirm access for each fee-for-service hospice NPI and identify any admissions awaiting attestation. Provider Enrollment · due Sep 8, 2026
2. Reconcile September elections to portal confirmations, retain informed consent, and escalate missed five-calendar-day submissions to DHCS. Clinical Operations · due Sep 8, 2026
3. Check submission timeliness and associated claim outcomes during the first month; internal review date is not a DHCS extension. Compliance · due Sep 30, 2026

Permalink: #medi-cal-ffs-hospice-attestation-portal · Development ID GC-2026-0032

AB 280 establishes provider directory reliance protections

What changed

California approved and filed AB 280 on September 27, with compliance under the amended directory provisions beginning July 1, 2027. The chaptered text directs DMHC to select a central utility and establish uniform standards for collecting, managing and checking provider-directory information. Subject to the specified exclusive-provider exception, plans and insurers must use the designated utility and submit directories for consistency reports; the methodology includes identifying inconsistent or incomplete entries, reviewing the report and describing remediation. Provider contracts must support information submission and identify the products in which a provider participates. The utility’s data does not excuse inaccurate network-status information in a carrier’s own directory. Qualifying nonprofit plans or insurers with at least 3.5 million enrollees or insureds in the specified geographic, mutually exclusive single-medical-group arrangement need not use the utility for providers exclusively serving, or employed by, the specified plan, insurer, medical group, facility or system. Providers contracted to multiple plans, or multiple insurers or plans under the insurer provision, remain subject to the utility requirement.

For covered benefits obtained in reasonable reliance on materially inaccurate, incomplete or misleading directory information, the regulatory finding triggers coverage and protection against charges beyond the applicable in-network share. Reimbursement is the agreed amount or, absent agreement, the reasonable and customary amount, less that share; covered-service status remains necessary. The text also addresses verification notices, accurate reinstatement requests within ten business days and a possible warning after five calendar days without a response. General acute care hospitals are exempt from specified confirmation, removal and reinstatement paragraphs, rather than the entire directory section. The amendments added by AB 280 do not apply to Medi-Cal managed care contracts. These future requirements call for product-specific preparation as of October 4.

Why it matters

Directory accuracy affects access, member liability and provider reimbursement. Utility integration must be matched to the actual product scope and reliance protections.

Response type

Assess

Confidence

Moderate. Chaptered September 27 text supports the July 1, 2027 compliance date, directory utility duties, reliance conditions and specified exclusions; implementing standards and affected-product assessment remain to be confirmed.

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Patient Access, Compliance, IT

Long lead justification

The expressly stated July 1, 2027 operative date exceeds 180 days, while central directory utility integration and member reliance workflows require advance implementation planning. (approved by Brandon Goulter, direct owner instruction executed by Codex, Oct 16, 2026)

What to do nextMap affected products and central-utility responsibilities, test member reliance and reimbursement workflows, and account for the specific hospital and Medi-Cal exclusions before July 1, 2027.

1. Confirm covered plan products, hospital exclusions and directory utility responsibilities. Managed Care · due Nov 1, 2026
2. Map directory accuracy, notice, reliance and reinstatement workflows to the final provisions. Patient Access · due Mar 1, 2027
3. Test integration and member-facing processes before the July 1 operative date. IT · due Jul 1, 2027

Permalink: #ab-280-health-care-coverage-provider-directories-gc-2026-0056 · Development ID GC-2026-0056

AB 350 expands fluoride treatment coverage and guidance

What changed

California approved AB 350 on September 27. For commercial contracts or policies issued, amended or renewed on or after January 1, 2027 that already cover fluoride varnish as a pediatric oral-care benefit, the enacted text requires medically necessary application without deductible, coinsurance, copayment or other cost sharing, whether billed as a medical or dental benefit. Specialized coverage and Medicare supplement coverage are excluded. The commercial plan section also excludes Medi-Cal managed care contracts. If the requirement creates a state obligation to defray costs, that requirement ceases to apply absent the specified appropriation; it does not make every product an unconditional new fluoride benefit.

The Medi-Cal provisions cover fluoride application or other department-defined fluoride treatment and other prophylaxis for children under 21. DHCS must issue billing guidance and necessary policy updates by July 1, 2027 consistent with EPSDT and subject to utilization management. The policy must allow varnish without place-of-service restrictions when a Medi-Cal enrolled, licensed medical or dental provider renders it, or when an eligible trained professional acts within scope under that provider’s supervision. Community health workers are included; additional nonlicensed practitioners depend on DHCS designation. The supervising provider bills, verifies training and retains documentation for review or audit. Implementation depends on necessary federal approvals and available federal participation, so the commercial contract date does not itself establish that Medi-Cal billing changes are ready.

Why it matters

Benefit configuration and pediatric access depend on different commercial and Medi-Cal conditions, provider qualifications and implementation milestones.

Response type

Assess

Confidence

Moderate. Chaptered September 27 text distinguishes qualifying commercial contract dates from Medi-Cal guidance, provider qualifications and federal conditions; implementing guidance and product applicability remain to be confirmed.

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Revenue Cycle, IT, Compliance, Clinical Operations

What to do nextPrepare commercial cost-sharing changes for qualifying 2027 contracts. Separately verify Medi-Cal provider enrollment, supervision, training records, federal conditions and DHCS billing guidance before changing claims rules.

1. Confirm affected benefits, contracts, statutory conditions and applicable dates. Managed Care · due Oct 18, 2026
2. Separate commercial benefit configuration from Medi-Cal implementation; confirm approved scope, provider eligibility and DHCS billing guidance before changing claims rules. Managed Care · due Jan 1, 2027
3. Test revised workflows and member or provider communications before implementation. Compliance · due Jan 1, 2027

Permalink: #ab-350-health-care-coverage-fluoride-treatments-gc-2026-0057 · Development ID GC-2026-0057

AB 1682 adds qualifying scalp cooling coverage

What changed

California approved and filed AB 1682 on September 27. The enacted commercial provisions apply to large-group plan contracts and insurance policies issued, amended or renewed on or after January 1, 2027. They require coverage for scalp cooling prescribed by a health care provider to reduce the incidence or severity of hair loss before, during or after treatment with alopecia-inducing chemotherapy. Copayments, coinsurance and deductibles remain permissible, but may be no less favorable than those for oncology supportive care under the same coverage. Specialized plans and policies are excluded from these commercial provisions.

The covered scalp-cooling definition requires an FDA-cleared device or system and expressly excludes non-cleared cold caps or products regardless of their marketing label. Medi-Cal managed care contracts fall under the separate WIC 14132.65 provision instead of the large-group mandate. That provision treats prescribed scalp cooling as a covered benefit subject to medical necessity and utilization controls, but implementation is conditioned on necessary federal approvals and available federal financial participation that is not jeopardized. DHCS may implement through letters, bulletins or similar instructions. As of October 4, the chaptered language supports preparation and monitoring of those conditions, rather than assuming every chemotherapy patient or product is already payable.

Why it matters

Oncology benefit and authorization rules need to identify eligible devices, contracts and cost sharing while distinguishing the conditional Medi-Cal pathway.

Response type

Assess

Confidence

Moderate. Chaptered September 27 text supports the large-group contract date, FDA-cleared device definition and separate conditional Medi-Cal provisions; operational coding and implementation guidance remain to be confirmed.

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Revenue Cycle, IT, Clinical Operations, Compliance

What to do nextIdentify qualifying large-group renewals, FDA-cleared devices and oncology supportive-care cost sharing. Track Medi-Cal federal approvals and DHCS implementation instructions before activating that pathway.

1. Confirm affected benefits, contracts, statutory conditions and applicable dates. Managed Care · due Oct 18, 2026
2. Confirm affected large-group benefits, medical necessity and coding; track Medi-Cal approvals and guidance rather than assuming immediate universal reimbursement. Managed Care · due Jan 1, 2027
3. Test revised workflows and member or provider communications before implementation. Compliance · due Jan 1, 2027

Permalink: #ab-1682-health-care-coverage-scalp-cooling-gc-2026-0064 · Development ID GC-2026-0064

AB 1876 strengthens health plan nondiscrimination protections

What changed

California approved and filed AB 1876 on September 30. The enacted provisions prohibit licensed plans and insurers from excluding people from enrollment or participation, denying benefits or discriminating on the basis of race, color, national origin, age, disability or sex. Sex discrimination includes sex characteristics and intersex traits, pregnancy or related conditions, sexual orientation, gender identity and sex stereotypes. The text addresses benefit design, marketing, claim decisions and cost sharing, as well as access based on recorded gender or sex assigned at birth. It prohibits categorical exclusions for all gender-transition or other gender-affirming care and discriminatory restrictions on specific such services.

The statute preserves a legitimate, nondiscriminatory reason to deny or limit a service, including clinical appropriateness and reasonable medical-management or medical-necessity requirements. A decision may not rest on unlawful bias or be a pretext for discrimination; open enrollment periods remain permitted. The coverage-document notice must state the nondiscrimination policy and explain grievance filing, with the applicable website and telephone number. Disability-related benefit design must also address the most integrated setting appropriate to the individual. As of October 4, this is enacted text for implementation planning; applicable commencement and regulatory instructions should be confirmed before treating every provision as already operative or interpreting it as universal coverage for every requested service.

Why it matters

Compliance review must test how coverage criteria operate in practice while preserving legitimate clinical and coverage decisions supported by nondiscriminatory reasons.

Response type

Assess

Confidence

Moderate. September 30 chaptered text supports the protected bases, conduct rules, notice duties and clinical/coverage exceptions; applicable commencement and implementation instructions remain to be confirmed.

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Compliance

Affected functions

Compliance, Legal, Managed Care, IT, Patient Access

What to do nextPrepare reviews of benefit exclusions, enrollment, claims, cost sharing and grievance notices. Confirm commencement and document clinical and coverage reasons consistently when revising policies.

1. Confirm affected benefits, contracts, statutory conditions and applicable dates. Compliance · due Oct 18, 2026
2. Test enrollment, benefit, claim and member service workflows against the protected bases; revise escalation and denial review controls. Managed Care · due Nov 15, 2026
3. Test revised workflows and member or provider communications before implementation. Compliance · due Dec 15, 2026

Permalink: #ab-1876-health-care-coverage-nondiscrimination-gc-2026-0068 · Development ID GC-2026-0068

AB 2499 sets a future electronic exchange standard for claim support

What changed

California enacted AB 2499 on September 30. Beginning May 26, 2028, the amended claim-payment provisions require plans and insurers to accept electronic medical records and supporting documentation necessary to process a claim through a standard electronic submission method. The method may use a designated portal or the specified state and federal interoperability standards. Its file-size limits must be sufficient for medical records and supporting documents typically needed for claims, and the system must confirm electronic receipt. If a state or federal standard specifically governing file size, number or other submission capacity is adopted, that standard applies.

The new protection prohibits denying, pending or delaying a claim solely because the carrier’s system cannot accept documentation that otherwise meets its requirements. It preserves other lawful grounds for those actions and temporarily excepts circumstances beyond reasonable control, including power outages, natural disasters and cyberattacks. The chaptered text also reproduces payment and contest rules, including existing 30-day provisions; the future electronic-document requirement should be implemented as an intake and processing change rather than assumed to replace every claim deadline. As of October 4, the May 2028 start supports advance interface and vendor planning, without implying the new exchange duty is already in force.

Why it matters

Claims attachment capacity, receipt evidence and exception handling can affect processing even when the underlying claim and payment rules are unchanged.

Response type

Assess

Confidence

Moderate. September 30 chaptered text states the May 26, 2028 electronic-support start and the system-capacity, receipt and exception rules; future standards and implementation details remain to be monitored.

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, IT, Managed Care, Compliance, Finance

Long lead justification

The law expressly begins standardized claim support exchange on May 26, 2028, beyond 180 days; advance attachment standards, vendor dependencies and interface planning warrant retaining the implementation item. (approved by Brandon Goulter, direct owner instruction executed by Codex, Oct 16, 2026)

What to do nextInventory attachment formats, portal capacity, receipt confirmations and vendor dependencies. Plan tests for the May 26, 2028 requirement, preserving other lawful claim edits and documented outage handling.

1. Inventory supporting claim information formats and affected payer interfaces. Revenue Cycle · due Nov 15, 2026
2. Confirm the final exchange standard and vendor dependencies as implementation specifications become available. IT · due Jun 1, 2027
3. Test affected claims support workflows before the expressly stated operative date. Compliance · due May 26, 2028

Permalink: #ab-2499-health-care-coverage-claims-payments-gc-2026-0078 · Development ID GC-2026-0078

CMS announces broad state participation in the GENEROUS Medicaid drug payment model and a September 30 signing date

What changed

CMS announced September 18 that all 50 states, the District of Columbia and Puerto Rico had applied for the GENEROUS Medicaid drug-payment model. Forty states and Puerto Rico had signed participation agreements at the time of that release, with the remainder given until September 30. CMS describes the model as having launched in January 2026 for five years and estimates $64.3 billion in taxpayer savings over ten years. The estimate is a forecast, and the broad application count is distinct from the smaller signed-agreement count reported on September 18.

Participating manufacturers make covered outpatient drugs available to participating state programs at most-favored-nation prices through supplemental rebates invoiced under state agreements. CMS monitors pricing accuracy and shares in the rebates through a reduction in the federal share of Medicaid payments. Those mechanics create state, manufacturer and federal accounting dependencies rather than an automatic new provider payment rate. As of October 4, the September 30 signing date has passed; this release alone does not identify California’s final agreement status or establish that every applicant signed. State-specific terms and operational instructions remain necessary to assess downstream effects.

Why it matters

Rebate invoicing, pricing verification and federal-share reconciliation can change financial operations without automatically changing every formulary or provider claim.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal, California

Primary owner

Managed Care

Affected functions

Managed Care, Clinical Operations, Finance, Compliance, IT

First seen

Sep 20, 2026

Last materially changed

Sep 20, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextVerify California’s actual agreement and implementation instructions after the September 30 milestone. Map supplemental rebates and federal-share reconciliation before changing forecasts or downstream operational rules.

1. Confirm California participation status and the state implementation contact. Managed Care · due Sep 23, 2026
2. Map supplemental-rebate invoicing, manufacturer data, and federal-share reconciliation dependencies. Finance · due Sep 30, 2026
3. Monitor DHCS instructions for formulary, claims, or reporting changes. Clinical Operations · due Oct 7, 2026

Permalink: #cms-generous-medicaid-drug-model-participation · Development ID GC-2026-0106

CMS expands ACCESS to heart failure, COPD, substance use disorder, nicotine dependence, and extended musculoskeletal care in spring 2027

What changed

CMS’s September 15 announcement expands ACCESS in spring 2027 to heart failure, COPD, substance use disorders and nicotine dependence, with extended support for specified chronic musculoskeletal conditions beyond the initial 12-month care period. The voluntary Original Medicare model ties payment to measurable health outcomes rather than only individual services. Participants may offer virtual care, coaching, remote monitoring and connected devices between regular visits, coordinated with the broader care team. The new tracks are announced future options as of October 4, rather than evidence that all such services are already available through the expansion.

CMS says participation does not negatively alter a beneficiary’s benefits, coverage or provider choice, and primary care clinicians can refer eligible people to participating organizations. Medicare Advantage enrollees are not eligible for ACCESS itself, though plans may offer similar programs; the announcement separately describes payer pledges to align outcome-based payment. CMS reported 160 participating organizations at launch and a directory of organizations and conditions. Service-line readiness therefore depends on the actual participant, track and beneficiary eligibility, together with clinical coordination and outcome measurement, not simply the presence of a chronic diagnosis or a wearable device.

Why it matters

Potential referrals and participation require coordinated clinical, device and outcomes-data workflows, with Original Medicare eligibility distinguished from similar payer programs.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Managed Care, IT, Compliance, Finance

First seen

Sep 20, 2026

Last materially changed

Sep 20, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextIdentify service-line and referral owners, confirm participant and condition availability, and assess consent, clinical oversight, data and device readiness as CMS develops the new track specifications.

1. Assign service-line owners for the five added ACCESS tracks. Clinical Operations · due Oct 4, 2026
2. Assess referral, consent, remote-monitoring, device, and outcomes-data readiness. IT · due Oct 18, 2026
3. Prepare a participation or referral recommendation when CMS posts track specifications. Managed Care · due Nov 1, 2026

Permalink: #cms-access-model-new-chronic-condition-tracks · Development ID GC-2026-0107

CMS replaces October EDI instructions to update the 276/277 flat-file attachment

What changed

CMS rescinded September 18 Transmittal 13967 and replaced it with September 28 Transmittal 13977 for the October EDI front-end update, CR 14429. The latest cover states that the change updates the 276/277 flat-file attachment and that all other information remains the same. The September 18 predecessor had itself replaced the August 27 version to correct two typographical errors in the edits spreadsheet. These are successive revisions with different stated purposes. The current instruction is effective October 1, 2026, with systems implementation October 5.

The recurring update supplies common front-end HIPAA edits for Part A and Part B contractors and CEDI and directs shared-system updates. The requirements address TA1 and 999 acknowledgment handling, updated edit spreadsheets and the institutional and 276/277 flat-file layouts; the contractor change log identifies the quarterly modifications. Acceptance at the transaction-validation stage is not a claim payment or coverage decision. As of October 4, organizations should verify that vendor materials incorporate the final September 28 attachment and reconcile actual deployment with the October 5 implementation milestone instead of treating an older spreadsheet check as completion of the latest revision.

Why it matters

Version control across clearinghouse and billing interfaces can affect acknowledgment and claim-status handling even where underlying coverage is unchanged.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, IT, Compliance, Finance

What to do nextVerify deployment of the September 28 replacement and current attachment before October 5, test affected front-end and 276/277 scenarios, and monitor acknowledgments and exceptions.

1. Internal target: obtain the September 28 R13977 replacement and current 276/277 flat-file attachment; compare them with superseded vendor materials while preserving October 1 applicability. Revenue Cycle · due Oct 4, 2026
2. Internal target: regression-test current front-end and 276/277 claim-status scenarios with IT and vendors against the September 28 attachment. IT · due Oct 5, 2026
3. Validate actual deployment and acknowledgment/exception monitoring against the October 5 CMS implementation date; record unresolved exceptions and follow-up without assuming deployment is complete. Revenue Cycle · due Oct 5, 2026

Permalink: #cms-october-2026-edi-front-end-edits-corrected · Development ID GC-2026-0108

California limits added billing barriers for Medi-Cal providers after other coverage pays

What changed

California approved and filed AB 1126 on September 14. For a Medi-Cal managed care enrollee with other coverage where Medi-Cal is payer of last resort, DHCS must ensure a noncontracted provider billing allowable costs unpaid by that coverage does not face administrative requirements significantly exceeding those for billing the same costs through fee-for-service Medi-Cal. A separate provision says a participating Medi-Cal fee-for-service provider need not join the managed care network simply to bill allowable covered costs, but this specific no-contract requirement excludes Medicare as the other coverage. The distinction matters when applying coordination-of-benefits procedures.

Plans may require a letter or similar agreement for prior-authorized services, services covered by the Medi-Cal plan but not the other coverage, and qualifying continuity-of-care or completion-of-services arrangements. Without an agreement, the provider may bear amounts above the allowable fee-for-service rate or service limits and may not bill the enrollee for the unpaid excess. DHCS must clarify billing conditions, may use letters or bulletins, and must update legislative health committees annually from 2027 through 2030. Implementation is expressly limited to necessary federal approvals and available federal financial participation that is not jeopardized. As of October 4, the chapter text does not establish that those conditions have been met or set a separate January 1 implementation deadline.

Why it matters

Coordination-of-benefits edits must distinguish the general administrative limit from the narrower no-contract rule and preserve lawful agreement and beneficiary-billing safeguards.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Revenue Cycle, Compliance, IT

First seen

Sep 20, 2026

Last materially changed

Sep 20, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextCompare noncontracted-provider edits and agreements with each statutory condition, including the Medicare distinction. Prepare changes pending applicable commencement, required federal approvals, funding and DHCS instructions.

1. Map noncontracted-provider billing requirements after other coverage pays. Managed Care · due Oct 16, 2026
2. Identify edits or network requirements that exceed fee-for-service rules. Revenue Cycle · due Oct 30, 2026
3. Prepare implementation pending federal approval and funding. Compliance · due Nov 13, 2026

Permalink: #ab-1126-medi-cal-other-coverage-billing · Development ID GC-2026-0111

CMS names final 2027 mandatory Ambulatory Specialty Model participants and reporting steps

What changed

The September 17 MLN Connects newsletter announced the final participant list for the mandatory Ambulatory Specialty Model’s 2027 performance year. CMS directs specialists who frequently treat Original Medicare patients for outpatient low back pain or heart failure to check whether they were selected. Selection carries all applicable model requirements, including required measure reporting and attestations. The newsletter’s announcement of a final list is a participation and readiness event; it does not make every clinician who treats either condition a participant without checking the actual selection.

CMS states that participants’ future Medicare Part B payments will be adjusted based on performance on reported measures and activities. That links data and attestation readiness to later payment consequences while preserving the distinction between a performance year and the future payment adjustment. The newsletter also offered a September 30 office hour and linked the model’s participant, model and FAQ pages. As of October 4, that event date has passed, but selected organizations still need to identify applicable specifications and reporting responsibilities before the 2027 performance year. The newsletter itself does not list every individual reporting deadline.

Why it matters

Selected specialists need clear ownership of measure data, attestations and financial modeling before performance begins.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Quality, Finance, IT, Compliance

First seen

Sep 20, 2026

Last materially changed

Sep 20, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextCheck the final participant list, assign accountable clinical and reporting owners, obtain the applicable CMS specifications and calendar actual deadlines before testing source data for 2027.

1. Confirm whether the organization appears on the final participant list. Clinical Operations · due Oct 2, 2026
2. Inventory reporting and attestation requirements. Quality · due Oct 16, 2026
3. Test measure and payment source data. IT · due Nov 13, 2026

Permalink: #cms-ambulatory-specialty-model-2027 · Development ID GC-2026-0117

Noridian aligns JE nerve policies and revises facet-joint and MolDX articles

What changed

Noridian’s September 17 JE notices finalize Peripheral Nerve Injections and Procedures for Chronic Pain LCD L40265 for November 1 and retire Nerve Blockade for Treatment of Chronic Pain and Neuropathy LCD L35456 and article A56034 on October 31 because their material is addressed by the new LCD. The final notice says coverage is limited and reflects an evidence-based update incorporating procedures and literature. The notices establish a policy transition, not payment for every peripheral nerve procedure. Applicability and documentation require the governing policy version and contractor jurisdiction for the service.

The same day, facet-joint article A58403 revision 9 became effective, adding coding instructions for neurolytic destruction involving the T12-L1 and L1-L2 facet joints and revising the related code-pairing instruction. MolDX multiple-genes article A58120 revision 5 was also effective September 17, but its stated change was a revised hyperlink, not new clinical eligibility criteria. As of October 4, the article revisions are effective while the nerve-policy retirement and replacement remain future milestones. Coding teams should assess the distinct changes rather than treating all four notices as new coverage mandates or importing later October conforming articles into this issue.

Why it matters

Different changes require different controls: future clinical policy transition, current coding guidance and an administrative link update should not produce the same edit changes.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal, California

Primary owner

Coding

Affected functions

Coding, Revenue Cycle, Utilization Management, Clinical Operations, Compliance

First seen

Sep 20, 2026

Last materially changed

Sep 20, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextCompare the final nerve-policy transition and relevant dates with current documentation tools, check the facet-joint coding revision, and verify the MolDX link without assuming it changes coverage criteria.

1. Identify affected nerve-procedure and molecular-diagnostic services. Coding · due Oct 2, 2026
2. Compare local edits and documentation tools with all four revisions. Utilization Management · due Oct 16, 2026
3. Deploy and verify changes before the November 1 effective date. Revenue Cycle · due Oct 30, 2026

Permalink: #noridian-je-september-17-coverage-updates · Development ID GC-2026-0119

DHCS prepares a January 1 transition to fee-for-service for specified immigration-status coverage

What changed

DHCS’s September 29 provider notice adds a resource page for the January 1, 2027 transition of Medi-Cal members with unsatisfactory immigration status from managed care to fee-for-service. It emphasizes that this changes how care is delivered, not whether members remain eligible, and says members keep full-scope coverage if they renew on time. The September stakeholder news separately described the January transition, member and provider resources and a September 30 readiness webinar. As of October 4, the webinar date has passed; the transition itself remains ahead.

The provider notice warns that organizations billing only through managed care, without Medi-Cal fee-for-service enrollment, cannot continue caring for affected members after December 31, 2026. It directs providers to update PAVE enrollment, confirm screening and revalidation, review fee-for-service billing including Treatment Authorization Requests, and update capacity information for new fee-for-service members. Enrollment, authorization and receiving-provider capacity therefore need coordinated review, while each member’s eligibility and renewal remain separately verified. A provider’s managed care contract by itself does not establish the enrollment needed for the new delivery arrangement.

Why it matters

Continuity can fail if member transitions are planned without validating fee-for-service enrollment, billing and provider capacity.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Patient Access, Revenue Cycle, Case Management, Compliance, IT

What to do nextVerify current PAVE fee-for-service enrollment, screening and revalidation, review TAR and billing workflows, and reconcile member-specific referrals and capacity before January 1.

1. Identify affected members and services; confirm eligibility and continuity requirements individually. Managed Care · due Oct 18, 2026
2. Confirm PAVE fee-for-service enrollment, screening and revalidation for every participating location and clinician. Provider Enrollment · due Nov 1, 2026
3. Reconcile authorizations, referral pathways and fee-for-service capacity before the transition. Clinical Operations · due Dec 31, 2026

Permalink: #dhcs-immigration-status-ffs-transition · Development ID GC-2026-0120

CMS issues FY 2027 IPPS and LTCH implementation instructions

What changed

CMS issued a September 29 correcting notice for the FY 2027 IPPS/LTCH rule, effective October 1, and replaced Transmittal 13930 with September 29 Transmittal 13969, CR 14592. The replacement revises its policy section and requirement 14592.13 to resolve typographical errors, with other information unchanged. It specifies October 1 effectiveness and October 5 implementation, generally applying the FY 2027 changes to discharges from October 1 through September 30, 2027 unless noted otherwise. The instruction directs contractors to use the correcting-document versions of tables and files when applicable, rather than assuming the original final-rule download remains current.

The correcting notice explains that an IPPS hospital had incorrectly been treated as converted to rural emergency status and another hospital’s canceled rural reclassification was misapplied. Restoring and correcting those data required recalculation of relative weights, wage indexes, budget-neutrality factors, standardized amounts, outlier and capital factors, as well as affected uncompensated-care calculations. LTCH area wage indexes also change because they use the same underlying wage data. The instruction includes Grouper and MCE version 44.0 and updated Pricer and provider-file work. As of October 4, teams should verify the corrected files and discharge-date logic and resolve implementation exceptions for October 5; this source review does not establish any organization’s deployment is complete.

Why it matters

A narrow source-data correction can propagate across payment factors, so finance and claims testing must reconcile the actual corrected file versions.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Finance, Coding, IT, Compliance

What to do nextVerify corrected CMS tables, Pricer, grouper and provider-file inputs, reconcile representative IPPS and LTCH claims by discharge date, and resolve outstanding changes for October 5 implementation.

1. Internal target: obtain the September 29 correcting-notice tables and R13969 replacement instruction; identify affected rates, grouper/MCE version 44.0, Pricer and provider-file inputs. Revenue Cycle · due Oct 4, 2026
2. Internal target: reconcile representative IPPS and LTCH test claims using corrected files and October 1 discharge applicability, documenting results and remaining exceptions. IT · due Oct 5, 2026
3. Validate actual corrected-file deployment against the October 5 CMS implementation date and reconcile financial exceptions; record status rather than assuming earlier production readiness proves this replacement is deployed. Finance · due Oct 5, 2026

Permalink: #fy2027-ipps-ltch-implementation · Development ID GC-2026-0123

DHCS explains reinstated asset limits for Pickle, DAC, and Disabled Widow or Widower groups

What changed

DHCS issued ACWDL 26-16 on September 17 for the Pickle, Disabled Adult Child and Disabled Widow/er Medi-Cal groups. Asset limits return no sooner than January 1, 2027 at $130,000 for one person plus $65,000 for each additional household member, up to ten people. For existing members, the test applies at the next annual renewal or an earlier change-in-circumstance redetermination when assets can be verified ex parte. Applications received before January 1 do not require asset verification merely because processing finishes later, and retroactive eligibility months before that date remain outside the restored test.

The letter requires a 90-day cure opportunity for renewal discontinuances due to missing asset information, with restoration if the person supplies it and is property eligible. It preserves protections for earlier renewals whose cure period crosses January 1 and limits new asset requests during unrelated change reviews. These groups follow SSI/SSP resource timing, with specified medical-expense and transfer rules; months January 2024–December 2026 are excluded from transfer review, which builds gradually to a full 30-month look-back by July 2029. Counties must avoid excess-property overpayment referrals for protected periods, use existing notice snippets, and CalSAWS must update by January 1. As of October 4, training must distinguish these protections from a blanket immediate asset test for every member.

Why it matters

Eligibility errors can arise from applying the right limit at the wrong time or overlooking ex parte, cure and protected-month rules.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Patient Access

Affected functions

Patient Access, Compliance, IT, Case Management

First seen

Sep 20, 2026

Last materially changed

Sep 20, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextMap the letter’s limits and group-specific timing into screening, notices and escalation. Test pre-January applications, 2027 renewals, change reviews, cure cases and transfer look-back treatment before implementation.

1. Map ACWDL 26-16 asset rules to affected eligibility groups. Patient Access · due Oct 9, 2026
2. Update procedures, notices, and escalation instructions. Compliance · due Oct 30, 2026
3. Test representative eligibility cases. IT · due Nov 20, 2026

Permalink: #dhcs-asset-limits-special-medi-cal-groups · Development ID GC-2026-0124

CMS releases preliminary 2027 Clinical Laboratory Fee Schedule rates

What changed

The September 24 MLN Connects newsletter announced preliminary calendar-year 2027 Clinical Laboratory Fee Schedule determinations and an October 21 deadline for feedback. It distinguishes preliminary determinations for new tests from final contractor 2026 gapfill recommendations for 2027 payment. Comments on new-test determinations go to the CLFS annual public-meeting mailbox, while payment reconsideration requests for the gapfill recommendations go to the separate CLFS inquiries mailbox. The two files and submission routes address different parts of the rate-setting process.

CMS states that once the final, complete 2027 fee schedule is posted, the gapfilled payment amount is final. As of October 4, the October 21 window is still open; the newsletter does not itself make all announced preliminary amounts final payment rates or establish coverage for the associated tests. Laboratories should identify which test and methodology each concern involves, compare expected volume and payment effects, and tie supporting evidence to the appropriate comment or reconsideration route before the applicable decision is finalized.

Why it matters

Using the correct route and rate status helps laboratories submit evidence before the decision point without treating preliminary figures as production payment rates.

Response type

Comment

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Clinical Operations, Revenue Cycle, Finance, Compliance

First seen

Sep 27, 2026

Last materially changed

Sep 27, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextCompare the relevant preliminary determinations and gapfill recommendations with current volume, assemble code-specific support, and submit to the proper CMS mailbox by October 21.

1. Model preliminary rates against current laboratory volume. Finance · due Oct 5, 2026
2. Identify codes needing comment or reconsideration and assemble support. Clinical Operations · due Oct 12, 2026
3. Submit any supported request before the CMS deadline. Revenue Cycle · due Oct 21, 2026

Permalink: #cms-cy2027-clfs-preliminary-rates · Development ID GC-2026-0132

DHCS seeks comment on payment responsibility for psychiatric emergency services

What changed

DHCS’s September 25 draft Behavioral Health Information Notice clarifies proposed guidance on managed care plans’ responsibility for emergency services, including psychiatric emergencies, and post-stabilization care. The notice index requests feedback by October 12. The draft cites existing No Wrong Door guidance, AB 1316 and the managed care contract and behavioral health memoranda of understanding; it is presented for comment rather than a newly final BHIN as of October 4. Its discussion includes emergency-room professional services and facility charges.

The draft excludes specialty mental health services provided after admission for inpatient psychiatric care from the described managed care payment responsibility. It addresses emergency screening and care within the facility’s capability and says necessary psychiatric emergency care is covered regardless of voluntary status or an LPS involuntary detention. For people not enrolled in a managed care plan, it identifies fee-for-service as payer for emergency services with the same inpatient specialty-service boundary. It also describes behavioral health plan monitoring and documentation expectations. These distinctions give hospitals, plans and counties concrete responsibility and handoff questions to test in comments without treating the draft as eliminating every existing payer distinction.

Why it matters

Payment disputes can arise where emergency stabilization and admitted inpatient psychiatric services cross delivery-system boundaries.

Response type

Comment

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Clinical Operations, Revenue Cycle, Compliance

First seen

Sep 27, 2026

Last materially changed

Sep 27, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextCompare emergency and post-stabilization responsibility, admission handoffs and documentation with the draft, identify actual disputes and submit supported feedback to DHCS by October 12.

1. Map current psychiatric emergency and post-stabilization payment workflows. Managed Care · due Oct 2, 2026
2. Identify disputed responsibility rules and operational gaps. Clinical Operations · due Oct 7, 2026
3. Submit supported feedback to DHCS. Compliance · due Oct 12, 2026

Permalink: #dhcs-draft-psychiatric-emergency-payment-responsibility · Development ID GC-2026-0135

GLOBE final model: manufacturer rebates and selected Part B drug coinsurance preparation

What changed

CMS published the GLOBE final rule October 2, with regulatory effectiveness November 30, 2026. The model begins January 1, 2027 with voluntary manufacturer international net-pricing data submission; its five performance years run April 1, 2027 through March 31, 2032, with associated rebate payment and reconciliation extending through March 31, 2034. It tests an alternative calculation for manufacturer Part B inflation rebates on selected separately payable drugs. Eligible single- or sole-source products must meet specified drug-category and spending criteria, beginning with a $100 million threshold, subject to exclusions including negotiated-price drugs, qualifying orphan-only indications, listed cell/gene therapies and plasma-derived products.

CMS selects geographic areas by ZIP-based random assignment representing about 25 percent of Original Medicare Part B beneficiaries, then determines individual eligibility. Original Medicare Part B must be primary; Medicare Advantage, cost/prepayment plans and other primary group coverage are excluded. Providers, suppliers and beneficiaries are not the manufacturer model participants, and providers continue buying and billing drugs while CMS determines applicable coinsurance adjustments. Reduced coinsurance uses the lesser relevant benchmark/inflation-adjusted amount when the statutory comparison triggers it, with Medicare payment adjusted accordingly and other claim adjustments and the deductible preserved. As of October 4, drug and beneficiary selection and implementation guidance remain necessary before changing patient estimates; the model is not a universal replacement of Part B rates.

Why it matters

Manufacturer rebate obligations and provider collection changes involve different actors and dates, and patient liability depends on selected drugs and beneficiaries.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Finance

Affected functions

Finance, Revenue Cycle, Clinical Operations, Managed Care

What to do nextInventory potentially affected drugs, track CMS selection and instructions, and prepare coinsurance and patient-estimate controls for the April performance period while separately assessing manufacturer responsibilities.

1. Inventory potentially affected drugs and contracts, monitor CMS selection and implementation guidance, and test beneficiary coinsurance workflows before the applicable payment quarter. Finance · due Jan 1, 2027
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #globe-final-model-manufacturer-rebates-and-selected-part-b-drug-coinsurance-preparation · Development ID GC-2026-0143

FY 2027 IPF payment correction changes per diem and ECT amounts

What changed

CMS’s October 1 correction to the FY 2027 inpatient psychiatric facility rule is effective that day. The national per diem changes from $912.40 to $912.13, with the non-quality-reporting amount changing from $894.56 to $894.29. Electroconvulsive therapy payment changes from $688.59 to $688.38 per treatment, and its non-reporting amount changes from $675.13 to $674.93. The wage-index budget-neutrality factor changes from 0.9989 to 0.9986. These are corrected inputs to the adopted payment system, not a newly introduced IPF payment methodology.

The notice traces the error to an IPPS hospital wrongly treated as having converted to a rural emergency hospital, which excluded its wage data and affected the IPF wage index for the identified Mississippi area. Recalculation then changed national budget neutrality and payment amounts. CMS also corrects the poisoning comorbidity code count, the nonqualifying-emergency-department adjustment factor and impact analysis. As of October 4, an affected provider’s payment still depends on the appropriate geographic and facility factors and quality-reporting status, so checking only the national base amount is insufficient to reconcile claims.

Why it matters

Small national-rate corrections can create systematic discrepancies, while provider-specific factors determine the actual claim effect.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextCompare current IPF tables and October claims with the corrected national, wage and facility factors, including the appropriate quality-reporting adjustment.

1. Compare IPF rate tables and October claims against the corrected notice and verify quality-reporting adjustments. Revenue Cycle · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #fy-2027-ipf-payment-correction-changes-per-diem-and-ect-amounts · Development ID GC-2026-0144

FY 2027 IRF correction revises conversion and outlier amounts

What changed

CMS’s October 1 correction to the FY 2027 inpatient rehabilitation facility rule is effective that day. It changes the standard payment conversion factor from $19,868 to $19,866 and the outlier threshold from $8,857 to $8,856. The corresponding intermediate conversion figure changes from $19,888 to $19,886, and the identified budget-neutrality factor changes from 1.0036 to 1.0035. The notice also replaces related payment, worked-example and impact tables and corrects stated wage-adjustment factors. Those changes must be reconciled as a set rather than applying the two-dollar base change alone.

CMS explains that an IPPS hospital’s wage data had been omitted because it was incorrectly classified as a rural emergency hospital. Restoring it changed the pre-floor, pre-reclassified wage index used in IRF calculations, leading to revised budget neutrality and outlier calculations. The correction also removes erroneous text about public-reporting deadlines from the separate request-for-information discussion. CMS describes this as implementing the previously adopted methodology correctly, not a substantive new payment policy. As of October 4, finance and billing teams should verify the corrected versions and patient-specific case-mix and facility inputs before assessing a claim discrepancy.

Why it matters

The correction affects more than the headline conversion factor, so isolated adjustments can leave payment models and claims inconsistent.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextValidate the IRF pricer and modeling inputs against the corrected tables and factors, then reconcile representative October claims and outlier calculations.

1. Validate IRF pricer and contract modeling against the complete corrected tables and sample October claims. Revenue Cycle · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #fy-2027-irf-correction-revises-conversion-and-outlier-amounts · Development ID GC-2026-0145

Hospice FY 2027 corrected rates and 2.3-percent all-hospice impact estimate

What changed

CMS replaced Transmittal 13924 with September 30 Transmittal 13976, CR 14557, updating FY 2027 hospice payment tables after the hospice wage-index recalculation. The instruction is effective October 1 with October 5 implementation. The base update remains 2.3 percent, derived from the 3.2-percent market basket less 0.9 percentage point for productivity. Hospices failing quality reporting receive a four-percentage-point reduction, producing a negative 1.7-percent update. The FY 2027 aggregate cap is $36,174.75, with the cap year aligned to October 1 through September 30.

The separate September 30 Federal Register correction explains that omitted hospital wage data required recalculating hospice wage indexes, standardization factors and national rates by level of care, including the non-reporting tables. Corrected Table 22 estimates a 2.3-percent overall total impact for all hospices. Its 20,000-or-more routine-home-care-day subgroup has a negative 0.1-percent wage-data effect and a 2.2-percent total impact; other subgroup estimates also vary. These aggregate and subgroup estimates do not determine an individual hospice’s wage-adjusted claim payment. The instruction preserves geographic wage adjustments and county-specific transition-code handling where applicable. As of October 4, teams need the current replacement tables, correct location and quality status, and validation against the October 5 implementation milestone.

Why it matters

The all-hospice estimate, subgroup impacts, wage-adjusted rates and quality reductions describe different levels of analysis. Applying a subgroup estimate as a universal rate could misstate budgets and claims.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextReconcile the September 30 replacement tables, geographic and transition-code inputs, quality status and cap amount. Use the 2.3-percent all-hospice and applicable subgroup estimates for their stated budgeting scope, and validate actual October 5 implementation with the hospice-specific rate.

1. Reconcile corrected wage-adjusted rates, quality-reporting status and cap instructions; validate actual deployment against the October 5 implementation date. Distinguish Table 22’s 2.3-percent all-hospice impact from the 2.2-percent large-hospice subgroup estimate and the individual claim rate. Revenue Cycle · due Oct 5, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #hospice-fy-2027-payments-and-corrected-aggregate-impact-estimate · Development ID GC-2026-0146

CMS clarifies Medicare priority relative to FEHBP for federal annuitants receiving OWCP benefits

What changed

CMS issued October 2 Transmittal 13981, CR 14603, with November 2 effectiveness and implementation. It states Medicare is primary relative to FEHBP for federal annuitants who also receive federal workers-compensation benefits through OWCP. CMS explains that a 2022 OPM booklet change suggesting the reverse order conflicts with CMS’s current-employment guidance. The revised manual describes compensation recipients treated as annuitants who are deemed unable to return to work after six months, rather than treating every person receiving an OWCP benefit as a current employee.

This is the relative order between Medicare and FEHBP in that situation. The same manual section preserves Medicare’s separate exclusion where workers compensation has paid or can reasonably be expected to pay for the item or service, and notes that Medicare payment in such a case may be an overpayment. Beneficiaries also retain responsibilities to pursue available compensation benefits. As of October 4, registration and billing teams should prepare the November manual update while distinguishing annuitant/FEHBP status from whether the particular service belongs to a compensable injury claim; a single payer-order shortcut would miss that second inquiry.

Why it matters

Coverage order can be wrong if retiree status and OWCP receipt are conflated with current employment or if separate injury-related payment rules are ignored.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Patient Access

Affected functions

Patient Access, Revenue Cycle, Compliance

What to do nextReview annuitant status and the six-month unable-to-return condition in payer-order scripts, then route service-specific workers-compensation issues for separate MSP analysis before the November update.

1. Review federal-annuitant payer-order scripts and refer unusual workers compensation claims for separate MSP analysis. Patient Access · due Nov 2, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #cms-clarifies-medicare-priority-relative-to-fehbp-for-federal-annuitants-receiving-owcp-benefits · Development ID GC-2026-0147

Home health certification manual incorporates allowed practitioners

What changed

CMS’s September 30 Transmittal 13972, CR 14627, updates the Program Integrity Manual’s home-health sections effective and implementing November 2. It reflects CARES Act authority from March 2020 allowing nurse practitioners, clinical nurse specialists and physician assistants to order and certify eligibility and establish a plan of care. Contractors must accept qualifying documentation from these allowed practitioners. The manual update therefore aligns review instructions with existing authority, rather than creating a new 2026 scope-of-practice expansion or making every practitioner’s documentation sufficient by title alone.

Certification still needs support for homebound status, skilled care, the plan of care, supervision and a qualifying face-to-face encounter related to the primary home-health reason within 90 days before or 30 days after start of care. The manual requires supporting certifier or qualifying facility records; HHA-generated material alone is insufficient unless appropriately incorporated and signed off. Recertification does not cure an unsupported initial certification, and applicable financial-relationship restrictions remain. As of October 4, agencies should prepare the November instruction update by validating credentials and record flow while retaining the remaining eligibility and periodic recertification controls.

Why it matters

Admission and review processes must accept valid allowed-practitioner records without weakening the evidence needed to support payment.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Compliance, Provider Enrollment

What to do nextValidate templates, practitioner credentials, face-to-face timing and supporting-record incorporation against the revised manual, preserving financial-relationship and initial-certification requirements.

1. Validate certification templates, practitioner credentials and supporting medical records against the revised manual while preserving all other eligibility requirements. Clinical Operations · due Nov 2, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #home-health-certification-manual-incorporates-allowed-practitioners · Development ID GC-2026-0148

Medicare EDI manual supports the TCEDI gateway

What changed

CMS issued September 29 Transmittal 13954, CR 14590, to update Claims Processing Manual Chapter 24 for the Technical Consolidation of Electronic Data Interchange gateway. Effectiveness and implementation are October 30. The revision addresses commercial off-the-shelf software and translator references and updates sections covering telecommunications, common edits, claim numbering, receipt control, acknowledgments and outbound compliance checks. CMS explicitly says the instruction does not involve legislative or regulatory policy, so the manual revision should be read as technical implementation guidance.

The revised audience section explains that providers and trading partners may use the chapter, but its instructions primarily direct contractors and centralized Medicare EDI gateway operations, including TCEDI where designated. Contractor awareness of the revised manual is the stated business requirement. As of October 4, clearinghouses and billing teams can reconcile affected interfaces and acknowledgment handling with their MAC, but the transmittal does not itself establish that every provider must complete a new migration by October 30. Any organization-specific conversion sequence needs the actual contractor and trading-partner instructions.

Why it matters

Technical routing and acknowledgment changes can affect claim exchange without creating a new universal provider migration requirement.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

IT

Affected functions

IT, Revenue Cycle, Compliance

What to do nextReview applicable TCEDI and MAC instructions with the clearinghouse, test affected acknowledgments and contact routes, and distinguish contractor implementation from any separate provider conversion schedule.

1. Review the revised EDI manual with the clearinghouse and MAC. Test applicable acknowledgements and escalation contacts; do not infer an unsupported provider migration deadline from the manual revision. IT · due Oct 30, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #medicare-edi-manual-supports-the-tcedi-gateway · Development ID GC-2026-0150

January 2027 home health grouper uses version 08.0.27

What changed

CMS’s September 30 Transmittal 13974, CR 14631, supplies the January 2027 home-health Grouper update. version 08.0.27 applies to claim From dates on or after January 1,2027, with contractor implementation January 4. The specific business requirement covers home-health type-of-bill 032x claims other than 32A or 320. The claim From date controls the version selection described here; the contractor installation date does not shift applicability to services beginning January 4.

The Grouper assigns a Home Health Resource Group using reported claim and patient-assessment information, including diagnoses. CMS explains that annual diagnosis-code changes and later quarterly policy or code updates can require new software, and identifies its Grouper webpage for the software and documentation. As of October 4, this is an issued technical instruction for a future release, not proof that a vendor has installed it or a statement of every final payment-policy detail. Testing should use the correct claim types and boundary dates while reconciling the assessment and diagnosis inputs used by the software.

Why it matters

Version and date selection can change grouping even when software installation itself succeeds.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

IT

Affected functions

IT, Coding, Revenue Cycle, Clinical Operations

What to do nextSchedule the vendor release and test qualifying claim types and From dates around January 1, including assessment and diagnosis inputs, before January 4 contractor implementation.

1. Schedule vendor installation and regression checks for claim From dates straddling January 1, and reconcile grouping to CMS documentation. IT · due Jan 1, 2027
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #january-2027-home-health-grouper-uses-version-08-0-27 · Development ID GC-2026-0151

CMS issues January ASP, MPFS and ZIP-code system update instructions

What changed

CMS issued three September 29 instructions with a first January 1,2027 effective date and January 4 implementation. CR 14620 supplies Part B ASP and NOC drug-pricing files, including possible prior-quarter revisions. The files contain the applicable payment allowances, so contractors must not add another payment calculation; unlisted drugs follow the referenced manual rules. The instruction says contractors need not search and adjust already processed claims unless brought to their attention. The January release therefore does not by itself guarantee automatic reprocessing of every affected older claim.

CR 14618 directs downloading and testing the annual physician-fee-schedule datasets, including anesthesia, when CMS notifies contractors around the final-rule display, and readiness for up to three replacement datasets before January 4 unless otherwise directed. CR 14623 supplies quarterly ZIP5/ZIP9 and year-end files for geographic pricing, with April, July and October effective dates distinct from their implementation dates. CMS anticipates files roughly six weeks before each quarter and recognizes that newly created postal codes may still require the manual exception process. As of October 4, these are file-handling and readiness instructions; actual payment policy, released file versions and later corrections must be checked separately.

Why it matters

Separate file owners and version controls are needed for drug allowances, professional payment and geographic pricing, including any prior-quarter corrections.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

IT

Affected functions

IT, Revenue Cycle, Coding, Finance

What to do nextInventory the three releases, plan vendor and boundary-date tests, and track CMS availability notices and replacements. Review specific older-claim issues rather than assuming an automatic adjustment sweep.

1. Inventory the three releases and test the first January implementation. Monitor subsequent corrections and the applicable final payment policies separately. IT · due Jan 1, 2027
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #cms-issues-january-asp-mpfs-and-zip-code-system-update-instructions · Development ID GC-2026-0152

Acute Hospital Care at Home telehealth billing uses hospital POS 21

What changed

The October 1 MLN Connects newsletter directs billing of Acute Hospital Care at Home telehealth services with place-of-service21, inpatient hospital, and modifier 95 for synchronous telemedicine. CMS explains that AHCAH patients remain hospital inpatients even when care is delivered through telehealth at home. The patient’s physical location therefore does not alone change the service to ordinary home telehealth coding.

This guidance addresses the AHCAH inpatient context. Teams should preserve that distinction when charges pass from clinical documentation through professional billing interfaces, rather than automatically deriving a home place of service from an address or remote encounter flag. As of October 4, the newsletter is a current coding reminder; it does not itself establish AHCAH participation, medical necessity or a different payer’s rules for every home-based service.

Why it matters

Automatic home-telehealth mapping can conflict with the inpatient status of an AHCAH encounter.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextValidate AHCAH-specific POS21 and modifier95 mapping and professional billing interfaces, with documentation of the inpatient encounter and separate review of other payer requirements.

1. Validate AHCAH charge mapping, professional billing interfaces and payer-specific claim edits with the hospital billing team. Revenue Cycle · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #acute-hospital-care-at-home-telehealth-billing-uses-hospital-pos-21 · Development ID GC-2026-0153

Short-term acute care PEPPER report is available through CMS identity controls

What changed

The October 1 MLN Connects newsletter announces the Q2 fiscal-year 2026 PEPPER report for short-term acute-care hospitals. CMS describes the report as a tool to review billing accuracy, locate patterns needing monitoring or internal audit, examine possible undercoding or overcoding and follow trends such as longer stays. A pattern or outlier is an indicator for record review rather than an audit determination or a repayment demand.

Authorized officials, access managers and approved staff end users can obtain the organization’s report through the PEPPER Portal. Staff users sign into CMS Identity and Access using existing NPPES or PECOS credentials, request the PEPPER business function for the organization and need authorized-official or access-manager approval. The Comparative Billing Report function may be requested concurrently. As of October 4, hospitals can assign access and review work through these controls and select documentation samples appropriate to their actual service mix before drawing a compliance conclusion.

Why it matters

Hospital-specific pattern review can focus clinical documentation and coding work without treating peer differences as established errors.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Compliance

Affected functions

Compliance, HIM/CDI, Revenue Cycle

What to do nextConfirm organization-approved portal access, review relevant hospital outliers with compliance and HIM/CDI, and document the record-based findings and any necessary correction.

1. Confirm authorized report access, review hospital-specific outlier areas and choose documentation samples with Compliance. Compliance · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #short-term-acute-care-pepper-report-is-available-through-cms-identity-controls · Development ID GC-2026-0154

Refugee medical assistance period corrected to twelve months

What changed

The Office of Refugee Resettlement’s October 1 notice corrects the July14 assistance-period notice from eight to twelve months for both Refugee Cash Assistance and Refugee Medical Assistance. ORR says it reached the twelve-month period after further review under 45 CFR 400.211 and identifies the specific references being corrected. The notice concerns these assistance programs rather than an across-the-board change to Medicaid eligibility.

Recipients are directed to implement the corrected period within thirty days of Federal Register publication, consistent with the cited regulation. As of October 4, that implementation window remains open. Eligibility and patient-assistance teams should identify cases governed by the affected programs and reconcile state implementation instructions before communicating a duration or changing a case; the correction itself does not establish any particular person’s complete eligibility.

Why it matters

Using the erroneous duration could shorten assistance for affected cases, while other coverage pathways retain their own eligibility rules.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Patient Access

Affected functions

Patient Access, Case Management, Compliance

What to do nextReview affected refugee-assistance cases and the applicable state implementation instructions, correct duration references and coordinate outreach within the thirty-day implementation window.

1. Review applicable refugee medical assistance cases and reconcile state implementation and outreach instructions before changing eligibility workflows. Patient Access · due Oct 31, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #refugee-medical-assistance-period-corrected-to-twelve-months · Development ID GC-2026-0155

SNF FY 2027 correction revises wage-index calculations and burden estimates

What changed

CMS published a September 30 correction to the FY 2027 SNF payment rule, effective October 1. An IPPS hospital had incorrectly been classified as converted to a rural emergency hospital, excluding its wage data. Restoring the data required recalculating the SNF wage-index budget-neutrality factor and unadjusted and case-mix-adjusted federal per diem rates, along with worked payment examples. The notice changes the stated budget-neutrality factor from 0.9989 to 0.9988 and replaces the affected urban/rural rate and PDPM example tables. The displayed impact analysis is unchanged at its reported precision.

The same notice separately corrects QRP regulatory burden calculations that had used mean rather than median Bureau of Labor Statistics wages. Those labor-cost estimates describe the agency’s assessment of reporting burden and do not themselves add a new reporting requirement or change the adopted payment methodology. As of October 4, the relevant operational task is to reconcile the corrected wage and payment inputs while keeping burden estimates separate from claim rates. A single corrected factor cannot substitute for checking the complete applicable rate and facility inputs.

Why it matters

Correcting a wage-data classification can propagate through SNF payment tables, while burden-cost corrections have a different purpose.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextReconcile applicable SNF wage, budget-neutrality and rate files with the corrected publication and test representative October claims without treating revised QRP burden estimates as a new reporting duty.

1. Reconcile the affected FY 2027 SNF rate tables and wage-index calculations against the corrected publication. Revenue Cycle · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #snf-fy-2027-correction-revises-wage-index-calculations-and-burden-estimates · Development ID GC-2026-0192

California IRF ownership changes must preserve RCD selections and identifiers

What changed

Noridian’s September 28 guidance distinguishes accepting an existing Medicare provider agreement during an IRF ownership change from rejecting assignment and undergoing new-provider enrollment and survey steps. Where assignment is accepted in an active RCD state, the buyer continues the current review-choice selection and inherits the cycle’s reviews and affirmation decisions. Current and prior affirmation rates affect choices in the next cycle. Buyer and seller must coordinate if a selection period occurs before the ownership change is finalized, rather than assuming the transaction resets the demonstration history.

After finalization, Noridian directs use of the buyer’s current CCN/NPI combination for portal access and new unique tracking number requests. An NPI mismatch between the UTN and claim causes the claim to return, and a pre-change request needing an updated NPI should be raised with the Provider Contact Center. Administrators must also grant necessary staff portal permissions. Acceptance generally carries the existing provider agreement and CCN, so the instruction to use updated identifiers should not be read as proof every transaction creates a new CCN. As of October 4, RCD transition planning needs both inherited review status and consistent current billing identifiers.

Why it matters

An acquisition can preserve review obligations while changing access and billing identifiers, creating avoidable claim returns if those elements are not reconciled.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextInclude current RCD selection, affirmation history, selection-period coordination, portal permissions and UTN/NPI reconciliation in IRF acquisition and enrollment work, contacting Noridian for pending identifier changes.

1. Include RCD selections, prior affirmation rates, portal permissions and UTN/NPI continuity in IRF acquisition and enrollment checklists. Revenue Cycle · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #california-irf-ownership-changes-must-preserve-rcd-selections-and-identifiers · Development ID GC-2026-0199

Noridian October coding updates change FFR, infusion-pump and SAD billing

What changed

Noridian’s October 1 JE notices add 1086T, 1087T and 1104T to noninvasive fractional-flow-reserve article A58095. Infusion-pump article A55239 revision 27 updates Prialt/ziconotide and ropivacaine pricing for October 1–December 31 under the quarterly ASP file. Self-administered-drug article A53032 revision 48 deletes J1941 from its excluded-code list. Those notices describe different coding, pricing and exclusion-list changes; deletion from the SAD list alone does not establish that every patient, service setting or claim meets all remaining coverage and payment conditions.

The same-day ICD-10 notice adds, removes or revises diagnosis codes across multiple articles, including cardiac testing, imaging, rehabilitation, laboratory and wound care. Some changes replace broader codes with more specific descendants, so retaining an old code without checking its article and service date can misalign local edits. As of October 4, the notices are effective, but the full relevant article and underlying benefit or coverage policy still determine a claim’s treatment. Teams should verify the implemented version and the particular procedure, drug and diagnosis rather than apply one global rule to all four updates.

Why it matters

A shared effective date can conceal different changes that need separate clinical, code-table and pricing validation.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextVerify affected October procedure, diagnosis and price tables against each article and benefit rule, including the limits of the SAD deletion, and reconcile representative claims.

1. Update affected code and price tables and validate billing against each complete policy and benefit rule. Revenue Cycle · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #noridian-october-coding-updates-change-ffr-infusion-pump-and-sad-billing · Development ID GC-2026-0201

Medi-Cal updates maintenance dialysis billing for restricted-scope members

What changed

DHCS’s October 1 notice makes maintenance dialysis and transportation to and from dialysis clinics state-only covered benefits for members with unsatisfactory immigration status enrolled in restricted-scope Medi-Cal aid codes, regardless of age. It applies to service dates on or after October 1. The notice expressly preserves existing treatment of dialysis meeting the federal emergency-medical-condition definition, so the maintenance-dialysis update should not be used to restrict the unchanged emergency pathway.

Providers may hold affected dialysis and transportation claims until system changes are fully implemented. Alternatively, DHCS says it will implement an Erroneous Payment Correction process to automatically reprocess qualifying October 1-and-later claims; providers need not act on EPC-eligible claims unless future instructions say otherwise. Additional guidance is planned after system completion. As of October 4, that is a processing plan, not proof the update or reprocessing has finished. Eligibility, aid code, service type and dates still need confirmation, with tracking that prevents unnecessary duplicate submissions.

Why it matters

Coverage and system readiness can move on different schedules, making claim tracking and separation of emergency services important.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Patient Access, Clinical Operations, Managed Care

What to do nextIdentify qualifying maintenance dialysis and transport claims, verify member aid-code and service-date conditions, and follow DHCS hold/EPC instructions without automatic duplicate resubmission or changes to emergency access.

1. Identify restricted-scope maintenance dialysis and transportation claims with October 1 and later service dates. Revenue Cycle · due Oct 18, 2026
2. Confirm eligibility and aid-code treatment without changing emergency dialysis access. Patient Access · due Oct 18, 2026
3. Track system updates and EPC outcomes; prevent duplicate resubmission absent a DHCS instruction. Clinical Operations · due Oct 18, 2026

Permalink: #medi-cal-updates-maintenance-dialysis-billing-for-restricted-scope-members · Development ID GC-2026-0212

RHC and FQHC timeliness waiver opens for eligible LMFT and psychological associate claims

What changed

DHCS’s September 29 notice offers a one-time filing waiver for PPS-eligible RHC/FQHC psychological-associate services under a licensed clinical psychologist’s direction and supervision, for dates on or after January 1,2025. It also covers qualifying held LMFT claims unpaid under another billable service because the change-in-scope request requirement for adding LMFTs was eliminated under SPA 25-0009. The notice states a September 29–November 29 submission window. All coverage, scope, billing and identification requirements remain, so the waiver does not make every old mental-health claim payable.

The notice specifies revenue 0521 with T1015 or T1015 SE, and for the described dual-eligible members outside Medi-Cal managed care, revenue 900 or 529 with G0469 or G0470. Claims need a clinically appropriate diagnosis and informational-line procedure code, plus Box 80 wording identifying either the Psychological Associate or LMFT timeliness waiver. Psychological-associate claims require the supervising psychologist’s NPI and applicable supervision documentation. A medical or mental-health claim already submitted and adjudicated for the same member and day prevents the override. As of October 4, teams should screen for all conditions before using the open window rather than submit duplicates or assume a timely claim is necessarily covered.

Why it matters

The waiver can address eligible held claims, but accurate practitioner, code and same-day screening determines whether the limited override applies.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Coding, Clinical Operations, Compliance

What to do nextInventory qualifying unpaid encounters, exclude prior same-day adjudicated services, verify supervision and the exact code/remarks instructions, and submit eligible claims by the notice’s November 29 date.

1. Inventory eligible unpaid January 1, 2025 and later encounters and exclude previously adjudicated same-day applicable claims. Revenue Cycle · due Oct 18, 2026
2. Confirm supervision, rendering documentation and the specified T1015 or Medicare crossover code combination. Coding · due Oct 18, 2026
3. Use the exact Psychological Associate or LMFT timeliness-waiver remarks and submit eligible claims by November 29. Clinical Operations · due Nov 29, 2026

Permalink: #rhc-and-fqhc-timeliness-waiver-opens-for-eligible-lmft-and-psychological-associate-claims · Development ID GC-2026-0213

DOJ corporate fraud directive expands healthcare program-integrity targeting signals

What changed

DOJ’s October 1 Directive 26-12 tells Fraud Division prosecutors to prioritize healthcare fraud, controlled-substance distribution and Food, Drug and Cosmetic Act offenses alongside government, tax and trade fraud. The directive calls for close involvement of the Corporate Enforcement Section from case intake through resolution and gives it primary responsibility for evaluating compliance with corporate criminal resolutions. Management involvement, concealment, prolonged schemes, safety threats, multi-program effects and loss magnitude are among the stated considerations; they are nonexhaustive factors for prosecutorial decisions rather than automatic findings of corporate liability.

The seven-day instruction requires Fraud Division prosecutors to report ongoing corporate investigations to the section chief; new investigations and major developments require prompt notice. The footnote excludes certain district-fraud-counsel cases not supervised by the Division. The memorandum also directs leadership to develop whistleblower policies and follow existing corporate enforcement and voluntary-disclosure policy. As of October 4, these are internal enforcement instructions and targeting signals. They do not impose a new seven-day provider filing rule or replace an organization’s actual resolution terms, legal duties and case-specific disclosure analysis.

Why it matters

Management escalation, reliable records and compliance with actual resolution terms affect enforcement risk, while internal DOJ coordination deadlines must remain distinct from provider obligations.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Compliance

Affected functions

Compliance, Legal, Executive Leadership, Revenue Cycle

What to do nextReview escalation, program-integrity outliers and resolution compliance with counsel, applying actual disclosure duties and existing policies rather than treating the internal prosecutor timetable as an organizational deadline.

1. Brief compliance leadership on the corporate fraud priorities and escalation triggers. Compliance · due Oct 18, 2026
2. Reconcile billing-outlier monitoring with clinical and enrollment controls. Legal · due Oct 18, 2026
3. Review existing resolution requirements and voluntary-disclosure considerations with counsel, without treating the DOJ internal seven-day deadline as a provider duty. Executive Leadership · due Oct 18, 2026

Permalink: #doj-corporate-fraud-directive-expands-healthcare-program-integrity-targeting-signals · Development ID GC-2026-0214

SB 1049 gives qualifying claim corrections a minimum filing period

What changed

California approved and filed SB 1049 on September 30. The enacted text adds parallel plan and insurer provisions for a denial of a claim or part of one, or an overpayment notice, based wholly or partly on a defect that can be remedied through a corrected claim. In that situation, the claimant receives no less than 90 calendar days from the carrier’s most recent action to submit the correction. The trigger is the qualifying carrier action and remediable defect, rather than every original claim, general appeal or unrelated late filing.

A correction submitted in accordance with that provision may not be denied because it missed a different otherwise-applicable claim-filing deadline. A dispute concerning that corrected claim must remain eligible for the carrier’s fast, fair and cost-effective dispute-resolution mechanism. The law authorizes departmental guidance and regulations, including consistent DHCS guidance for the plan provision. It protects the correction window without guaranteeing payment where the underlying coverage or other claim requirements remain unsatisfied. As of October 4, this is enacted text for preparation; teams should confirm applicable commencement and instructions before treating the newly added provisions as already operative.

Why it matters

Correction queues need the precise defect and carrier-action dates so qualifying claims receive the protected submission period without confusing it with every other filing or dispute deadline.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Managed Care, Compliance

What to do nextPrepare to capture denial and overpayment notices, identify remediable defects and preserve corrected-claim submission evidence. Confirm commencement and update filing edits and dispute routes for qualifying corrections.

1. Confirm affected members, benefits and contracts against the final statutory scope. Revenue Cycle · due Oct 18, 2026
2. Map covered corrections, trigger dates and submission evidence; update work queues and payer communications. Managed Care · due Nov 15, 2026
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Dec 15, 2026

Permalink: #sb-1049-gives-qualifying-claim-corrections-a-minimum-filing-period · Development ID GC-2026-0242

AB 1629 changes noncontracted dental assignment of benefits

What changed

California approved and filed AB 1629 on September 27. Its new assignment provisions require direct payment to a noncontracting dental provider, including a registered dental hygienist in alternative practice, for covered services when an assignment is submitted under the statute. The pathway applies to contracts or policies covering out-of-network dental services; it does not create that benefit where absent. The plan provision excludes Medi-Cal managed care, including dental managed care. Before obtaining an assignment, the provider must explain noncontracted status, potentially lower patient costs in-network, estimated treatment and patient costs, possible lack of benefits, the right to confirm coverage, and the optional, prospectively revocable assignment.

The provider must retain signed, dated consent, although it need not be submitted to the carrier if the provider maintains the record. Before carrier payment, collection is limited to an estimate of the patient’s cost sharing or a deposit approximating it. Related professional-conduct provisions support those disclosures, consent and collection limits. Assignment transfers reimbursement rights for rendered services; it does not turn the provider into a network participant or guarantee coverage for treatment outside the benefit. As of October 4, this enacted text supports preparation of forms and payment handling, with applicable commencement confirmed before treating the new pathway as operative.

Why it matters

Patients and dental teams need accurate cost and coverage information before assigning payment, while carrier systems must recognize valid assignments within the covered benefit.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Patient Access, Compliance

What to do nextReview affected out-of-network benefits, consent disclosures, revocation handling, record retention and deposits. Confirm commencement and test direct-payment processing without implying network participation.

1. Confirm affected members, benefits and contracts against the final statutory scope. Revenue Cycle · due Oct 18, 2026
2. Review assignment documents, estimate disclosures and payment handling before applying the new pathway. Patient Access · due Nov 15, 2026
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Dec 15, 2026

Permalink: #ab-1629-changes-noncontracted-dental-assignment-of-benefits · Development ID GC-2026-0243

SB 950 adds qualifying dementia treatment coverage protections

What changed

California approved and filed SB 950 on September 27. Affected contracts and policies issued, amended or renewed on or after January 1, 2027 must cover medically necessary FDA-approved treatments or medications for Alzheimer’s disease or other conditions affecting memory, as determined by a health care provider. The protection reaches medical benefits and outpatient prescription benefits to the extent that outpatient drugs are covered. From January 1, step therapy is restricted for both self-administered and physician-administered treatments, but the statute does not require every treatment type to be available without it if at least one antiamyloid therapy is covered without step therapy.

Other utilization management, including prior authorization, remains permissible to determine medical necessity if applied in the same manner as for other covered illnesses. Coverage criteria may not be more restrictive than the FDA-approved indications, and qualifying authorization is treated as an exigent circumstance under the referenced review rules. The plan provisions exclude dental- or vision-only specialized plans, Medicare supplements and Medi-Cal managed care; the insurance section also lists limited-benefit policy exclusions. As of October 4, the January contract milestone calls for product and benefit preparation, while clinical eligibility and the specific step-therapy exception remain central to any individual request.

Why it matters

Neurology and pharmacy pathways need coordinated medical and drug benefit rules, expedited authorization handling and a properly scoped step-therapy design.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Compliance, Clinical Operations

What to do nextIdentify affected 2027 contracts and antiamyloid access, review FDA-indication criteria and exigent authorization routing, and preserve lawful medical-necessity review and statutory product exclusions.

1. Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · due Oct 18, 2026
2. Confirm covered contracts, FDA criteria and antiamyloid access; retain lawful review and member-specific medical necessity. Compliance · due Jan 1, 2027
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Jan 1, 2027

Permalink: #sb-950-adds-qualifying-dementia-treatment-coverage-protections · Development ID GC-2026-0244

AB 1843 limits prior authorization for covered hepatitis C antivirals

What changed

California approved and filed AB 1843 on September 27. The enacted plan and insurer provisions prohibit prior authorization for direct-acting antiviral drugs medically necessary to treat hepatitis C, subject to the statute’s therapeutic-equivalent exception. Where FDA has approved one or more therapeutic equivalents of a pangenotypic treatment, a carrier need not cover every therapeutically equivalent version without prior authorization if at least one pangenotypic and therapeutically equivalent version is available without it. The precise access rule therefore depends on the treatment and available equivalent, rather than a blanket removal of all pharmacy review.

The plan section expressly excludes Medi-Cal managed care contracts. The new restriction addresses prior authorization for the specified medically necessary hepatitis C drugs; it does not itself create coverage for every unrelated product or indication. As of October 4, it is enacted text for implementation preparation, with applicable commencement and any regulatory instructions to be confirmed. Pharmacy and clinical teams can identify affected edits now, but must distinguish the protected treatment pathway from lawful review of other versions under the exception and from requirements outside the statute’s scope.

Why it matters

A correctly configured exception can preserve prompt access to qualifying hepatitis C treatment without incorrectly treating every antiviral or therapeutic version as exempt.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Compliance, Clinical Operations

What to do nextConfirm commencement, affected products and the available pangenotypic equivalent pathway. Prepare prior-authorization edit changes and test dispensing and claims against the statutory exception.

1. Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · due Oct 18, 2026
2. Identify affected products and statutory scope, revise qualifying prior authorization edits and validate dispensing and claims workflows. Compliance · due Nov 15, 2026
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Dec 15, 2026

Permalink: #ab-1843-limits-prior-authorization-for-covered-hepatitis-c-antivirals · Development ID GC-2026-0245

AB 1887 sets rare disease drug authorization timing

What changed

California approved and filed AB 1887 on September 27. For contracts and policies issued, amended or renewed on or after January 1, 2027, a carrier must complete prior authorization within 30 days of the initial request when the prescription is the only FDA-approved treatment for a rare disease, an appropriate specialist prescribes it and determines it medically necessary. Rare disease means a condition affecting fewer than 200,000 people in the United States. The initial request occurs when the provider or staff sends it to the carrier or its delegate; the statute does not describe the clock as beginning only after a later internal intake milestone.

For a qualifying request, authorization must be immediately approved if no approval or denial decision has been made by the end of 30 days, or if a dispute with the provider or member remains ongoing then. The statute preserves the other referenced authorization timelines, so the 30-day backstop does not displace a faster applicable review obligation. The plan provision excludes Medi-Cal managed care contracts. As of October 4, teams should prepare for affected January renewals by preserving request dates, specialist and sole-approved-treatment support, and the escalation needed to recognize either immediate-approval trigger.

Why it matters

Specialty treatment delays can require a different result once the statutory backstop expires, making accurate request tracking and clinical eligibility documentation essential.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Compliance, Clinical Operations

What to do nextIdentify affected 2027 coverage, document specialist expertise and the only-FDA-approved-treatment condition, preserve initial transmission dates, and configure escalation for both 30-day approval triggers.

1. Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · due Oct 18, 2026
2. Confirm covered drugs, prescriber expertise and required request content; monitor response timing and escalate delays. Compliance · due Jan 1, 2027
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Jan 1, 2027

Permalink: #ab-1887-sets-rare-disease-drug-authorization-timing · Development ID GC-2026-0246

SB 964 creates a qualifying drug dose adjustment request pathway

What changed

California approved and filed SB 964 on September 27. The enacted text allows a treating contracting provider to request written authority to adjust a drug’s dose or frequency without prior authorization or subsequent utilization management. The carrier must respond in writing within 72 hours of receiving the request and authorize it when the request establishes every required condition. The drug must previously have been approved for that member’s serious chronic condition or cancer treatment, with the treating provider continuing to prescribe it for that condition. Opioids and scheduled controlled substances are excluded, and the dose must not have been adjusted more than twice without prior authorization.

The pathway also does not apply to an off-label use or adjustment unless it meets the additional conditions in the referenced off-label coverage provision. Medi-Cal managed care plans are excluded from the plan section. A qualifying written request and response therefore remain necessary; the law does not authorize unrestricted unilateral adjustments to every approved prescription or repeal all subsequent review. As of October 4, teams should prepare the evidence and response workflow while confirming applicable commencement before activating the new process.

Why it matters

Dose changes during ongoing chronic-condition or cancer care need reliable qualification and timing records so this access pathway is used within its limits.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Compliance, Clinical Operations

What to do nextPrepare a request template documenting prior coverage, condition, continued prescription, controlled-substance screening, adjustment history and any off-label criteria. Confirm commencement and track 72-hour written responses.

1. Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · due Oct 18, 2026
2. Create a qualifying request template, document each condition and track written responses for covered commercial products. Compliance · due Nov 15, 2026
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Dec 15, 2026

Permalink: #sb-964-creates-a-qualifying-drug-dose-adjustment-request-pathway · Development ID GC-2026-0247

SB 1094 changes biosimilar substitution and formulary requirements

What changed

California approved and filed SB 1094 on September 30. It permits pharmacist selection of a biosimilar or interchangeable biological product for a reference product when the prescriber has not prohibited substitution, subject to patient cost being no higher, patient communication and prescriber notification or electronic record entry within five days under the specified rules. The pharmacist retains responsibility for the selection, and the law preserves appropriate coverage controls. Separately, affected prescription-benefit contracts and policies issued, amended or renewed on or after January 1, 2027 must include at least one licensed biosimilar or interchangeable alternative for a formulary reference product when that alternative has lower net cost to the carrier.

For a carrier-directed trial of an alternative during continuing coverage, conditions include no prescriber substitution prohibition, lower net carrier cost, member cost sharing based on that net cost and no higher than the reference product, and at least 60 days’ advance notice with alternatives and exception instructions. Existing authorization for the reference product cannot simply require new authorization for the alternative, and the carrier cannot alter or issue a prescription. The text protects exception requests and bars exclusive use of an affiliated biosimilar when unaffiliated options exist. These continuing-coverage and switch sections exclude drugs prescribed for uses different from FDA marketing approval; those uses instead follow the separately referenced off-label coverage laws. It also sets January 15, 2027 provider notices and reporting beginning by October 1, 2027. As of October 4, dispensing authority, formulary implementation and continuity changes require separate preparation and commencement checks.

Why it matters

Substitution, formulary access and a carrier-required switch are different workflows, each with safeguards affecting prescriptions, member costs and continuity.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Compliance, Clinical Operations

What to do nextMap 2027 formulary requirements, prescriber instructions and notification systems. Test patient-cost limits, 60-day notices, exceptions, prior approvals and affiliated-product controls before implementing switches.

1. Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · due Oct 18, 2026
2. Reconcile dispensing authority, prescriber instructions, formulary selection and member continuity exceptions. Compliance · due Jan 1, 2027
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Jan 1, 2027

Permalink: #sb-1094-changes-biosimilar-substitution-and-formulary-requirements · Development ID GC-2026-0248

AB 1906 adds qualifying cervical screening home test coverage

What changed

California approved and filed AB 1906 on September 27. Affected commercial contracts and policies issued, amended or renewed on or after January 1, 2027 must cover cervical cancer screening ordered or provided by an in-network provider acting within scope and consistent with the referenced screening recommendations. The covered tests include Pap tests, FDA-approved HPV screening and FDA-authorized or cleared self-collected cervical screening kits usable outside a clinical setting. The text prohibits cost sharing for covered services under the section, subject to preservation of HSA-eligible high-deductible status. Specified specialized, vision-only, dental-only and Medicare supplement products are excluded; the commercial plan section excludes Medi-Cal managed care.

The separate Medi-Cal provisions address screening and authorized or cleared home kits on or after January 1, 2027, subject to medical necessity, utilization management and federal-law limits. Kits must be ordered or provided by the patient’s provider consistently with the screening recommendations and Medi-Cal policy, with clinically appropriate CPT or HCPCS billing. The kit provisions apply to fee-for-service and managed care, protect beneficiaries from cost sharing including share of cost or spend down, and depend on necessary federal approvals and available federal participation that is not jeopardized. DHCS may issue implementation instructions. As of October 4, neither the commercial contract date nor device authorization alone establishes readiness of every Medi-Cal payment pathway.

Why it matters

Access depends on approved test type, provider order, product scope and billing setup; commercial and Medi-Cal pathways have different conditions.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Managed Care

Affected functions

Managed Care, Compliance, Clinical Operations

What to do nextPrepare affected 2027 commercial benefits and HSA treatment, verify test authorization and provider requirements, and track Medi-Cal approvals, coding and DHCS guidance before activating claims changes.

1. Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · due Oct 18, 2026
2. Confirm order, network and kit requirements and benefit edits; track separate Medi-Cal implementation guidance. Compliance · due Jan 1, 2027
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Jan 1, 2027

Permalink: #ab-1906-adds-qualifying-cervical-screening-home-test-coverage · Development ID GC-2026-0249

AB 2348 revises Medi-Cal enhanced care management implementation

What changed

California approved and filed AB 2348 on September 27. The amended ECM and community-support provisions add public quarterly utilization, population and demographic reporting to the extent feasible, alongside annual reporting using statistically reliable data; the quarterly provisions become inoperative January 1, 2032. The text preserves ECM eligibility within applicable managed care contracts and the limits on duplicative high-intensity or targeted case management. It also retains the structure under which plans may elect DHCS-approved, cost-effective and medically appropriate community supports in lieu of covered services, without forcing a member to use a support or supplanting benefits outside the plan’s responsibility.

DHCS must maintain sufficiently detailed community-support policy guides and all-plan letters, and plans must adopt consistent policies and educate in-network support providers on requirements. The standard policy-update process calls for at least two weeks of public input, release of written changes at least six months before effectiveness, and January 1 or July 1 effective dates. DHCS may make an exception to ensure effective delivery but must notify stakeholders and give a rationale. By March 31, 2029, DHCS must provide legislative information to inform possible transition of supports into required benefits. That future evaluation is not itself a universal benefit mandate. As of October 4, teams should prepare for the enacted changes and confirm commencement and DHCS instructions.

Why it matters

Care-management delivery depends on consistent plan policies, provider training and reporting while preserving member choice and the program’s eligibility and benefit boundaries.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Case Management

Affected functions

Case Management, Managed Care, Compliance

What to do nextCompare current ECM and support policies, training and data flows with the enacted provisions. Track DHCS guidance updates, public-input periods and any justified exceptions before changing coverage.

1. Confirm affected members, benefits and contracts against the final statutory scope. Case Management · due Oct 18, 2026
2. Map existing ECM and community support workflows to the final provisions and subsequent DHCS instructions; validate training and plan reporting responsibilities. Managed Care · due Nov 15, 2026
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · due Dec 15, 2026

Permalink: #ab-2348-revises-medi-cal-enhanced-care-management-implementation · Development ID GC-2026-0250

October Medicare and Medi-Cal claims updates and Noridian service downtime

What changed

CMS's September 29, 2026 replacement instructions include R13978CP for OPPS and R13979CP for I/OCE version 27.3. The separate R13956CP instructions address the DMEPOS quarterly fee-schedule update. They identify October 1 effectiveness and October 5 systems implementation, subject to item-specific dates. The OPPS replacement adds revised policy language, requirements, education and tables; the I/OCE replacement finalizes attachments and adds two business requirements. September 28 R13977OTN also replaces earlier October EDI front-end instructions to update the 276/277 flat-file attachment. Updating a code file does not by itself establish coverage for every item or service.

Other October work includes laboratory fee-schedule/CLIA edits effective October 1, the home-health grouper version 07.2.26 and physician-fee-schedule code and indicator updates. DHCS's September 29 HCPCS notice applies listed benefit-code changes generally to October 1 dates of service, unless specified otherwise; its NCCI notice instead uses claims received on or after October 1. CMS MM14561 identifies October 5 implementation for SNF consolidated-billing changes, with individual table dates that must also be checked. Noridian's September 1 notice schedules CWF dark days October 2–4, limiting specified portal, IVR and customer-service functions, not every service. As of October 4 the scheduled window included that day; the notice alone does not prove restoration.

Why it matters

A single October release date misses distinctions among dates of service, claim receipt and systems implementation. Vendor confirmation needs to identify the actual file/version loaded.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal, California

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, IT, Coding, Finance

What to do nextReconcile current CMS and DHCS files with the claims and home-health system owners, test relevant codes and retain release confirmation. Use DHCS claim-received timing for NCCI and listed service dates for HCPCS. Confirm live availability after planned downtime and resolve any MAC/CMS date discrepancy before relying on a summary.

Permalink: #october-2026-medicare-claims-processing-updates · Development ID GC-2026-0012

2027 Medicare HCPCS quarterly instructions and clotting-factor fee distinguish service and implementation dates

What changed

CMS's August 27, 2026 transmittals distinguish the 2027 service dates from contractor implementation. R13938CP covers the January, April, July and October HCPCS releases: effective dates are the first of those months, while implementation dates are January 4, April 5, July 5 and October 4, 2027. Contractors retrieve files through the cloud after CMS email instructions, with updated files expected roughly six weeks before each quarter. This is an annual set of quarterly download instructions, not a rule that every 2027 HCPCS change becomes effective January 4.

R13937CP sets the 2027 clotting-factor furnishing fee at $0.270 per unit, effective January 1 and implementing January 4. CMS includes it in published national payment limits for clotting-factor codes. Where a separately payable factor has no limit in the ASP or NOC pricing files, the contractor pays for the factor and the furnishing fee; the manual also preserves the exception where furnishing costs are paid through another payment system. Payment logic must therefore distinguish an included fee from a separately added fee and use dates of service from January 1, rather than delaying applicability until the systems implementation date.

Why it matters

Service-date pricing and system implementation are different controls. A fee already included in a published limit should not be added again.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, IT, Coding, Finance

First seen

Aug 30, 2026

Last materially changed

Aug 30, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextAssign 2027 file and pricing owners, schedule the four HCPCS releases and test January 1 service-date pricing with January 4 implementation. Verify whether the clotting fee is included or separately payable before adding it.

Permalink: #january-2027-medicare-hcpcs-file-and-clotting-factor-updates · Development ID GC-2026-0014

Medicare colorectal biomarker coverage: June 8 effective date, January 4 claims implementation

What changed

CMS's August 27, 2026 NCD 210.3 instructions and September 2 MM14581 explain coverage for qualifying non-invasive biomarker colorectal screening from June 8, with claims-system implementation January 4, 2027. Coverage is once every three years for asymptomatic, average-risk patients aged 45–85 who meet all remaining criteria. A physician, physician assistant, nurse practitioner or clinical nurse specialist must order the test and use the results for management. Patients must receive information about performance and the importance of colonoscopy after a positive result. The NCD defines average risk through specified personal and family-history exclusions, rather than age alone.

The test must have FDA market authorization for colorectal screening, meet applicable FDA post-approval study requirements and be processed in a CLIA-certified lab. Its FDA-labeling performance must meet either sensitivity of at least 90% with specificity at least 87%, or sensitivity at least 79% with specificity at least 90%, compared with colonoscopy. MM14581 identifies ColoSense code 0421U, waived deductible and coinsurance, and bill types 13X,14X or 85X. MACs will not automatically search for affected June 8-onward claims, but may adjust claims brought to their attention. These conditions distinguish effective coverage, test eligibility and retrospective claim handling from the later systems release.

Why it matters

Claims and ordering screens need the full coverage criteria while preserving the earlier service-date entitlement and later implementation timing.

Response type

Implement

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Coding

Affected functions

Coding, Revenue Cycle, Clinical Operations, IT, Quality

First seen

Aug 30, 2026

Last materially changed

Aug 30, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextValidate patient, ordering, counseling and test criteria under NCD 210.3. Review eligible June 8-onward 0421U claims for contractor adjustment requests and prepare the January 4 systems changes.

Permalink: #ncd-210-3-colorectal-cancer-non-invasive-biomarker-tests · Development ID GC-2026-0013

CMS refreshes hospice telecommunications recertification reporting guidance

What changed

CMS revised MM14495 on September 2, 2026 to update the change-request release date, transmittal numbers and links, expressly making no substantive change to the article. The underlying instruction begins January 1, 2027, with January 4 systems implementation. It applies to hospice claims reporting face-to-face recertification encounters conducted through telecommunications by a hospice physician or hospice nurse practitioner. The September revision therefore refreshes implementation guidance rather than announcing a new September clinical eligibility standard.

The article directs reporting with G0679 and line-item detail, including a separately dated line for each service under the appropriate discipline's revenue code. MACs return claims using G0679 with a bill type other than 81X/82X or a revenue code other than 0657. The descriptor treats the encounter as an administrative expense; a reporting code does not by itself create a separately payable clinical visit. CMS also explains the statutory background for identifying virtual-platform encounters involving specified contractual or payment arrangements. Claim templates need to follow the operative code combinations and distinguish January 1 service applicability from the later systems release.

Why it matters

Correct bill-type and revenue-code combinations are needed to avoid returns. The guidance’s administrative-expense characterization should not be mistaken for a new separately payable visit.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Coding, Clinical Operations, IT

First seen

Sep 6, 2026

Last materially changed

Sep 6, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextValidate hospice claim templates, encounter dates and G0679/0657/bill-type combinations with the current instruction. Prepare January 1 applicability and January 4 implementation separately.

Permalink: #hospice-telecommunications-recertification-coding · Development ID GC-2026-0025

CMS collection comments: Medicaid-quality window closed; separate Part D and related window open until November 2

What changed

Two CMS notices have different comment clocks. The September 2, 2026 OMB-review notice for CMS-10249 and CMS-10553 closed October 2, before this edition. It concerns Money Follows the Person administrative reporting and Medicaid managed-care quality information, including state strategies, evaluations and quality-rating displays. The separate September 1 proposed-collection notice sets November 2, 2026 for comments. It covers retail drug acquisition-price surveys, Basic Health Program information and applications for 2028 Part D contracts, so that opportunity remained open as of October 4.

The September 1 notice describes monthly pharmacy acquisition-cost surveys supporting NADAC, proposed BHP information changes distinguishing funding from program eligibility, and applications used to assess Part D applicants or service-area expansions. Organizations must still satisfy the relevant application and CMS approval processes; a PRA notice does not award a contract. Both notices invite review of collection usefulness, burden and information quality. Closing the October 2 opportunity neither adopts those proposed revisions nor closes the November 2 opportunity, and the two notices should not be given one shared deadline.

Why it matters

Different collection stages and deadlines require separate comment decisions. These notices do not themselves establish a new provider implementation deadline or award a 2028 contract.

Response type

Comment

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Managed Care

Affected functions

Managed Care, Compliance, Finance

First seen

Sep 6, 2026

Last materially changed

Oct 4, 2026

Why it is still here

The separate September 1 retail-pricing, BHP and 2028 Part D application collection notice remains open for comments until November 2, 2026 as of this October 4 edition.

What to do nextRetain any October 2 submissions and assess the September 1 supporting forms for a November 2 comment decision. Identify the exact collection and submit through the notice’s specified route.

Permalink: #cms-pra-medicaid-quality-partd-applications · Development ID GC-2026-0026

CMS explains January Medicare Secondary Payer adjustment-code processing

What changed

CMS released MM14553 on September 4, 2026 for the August 21 change request governing certain Medicare Secondary Payer claim adjustment reason codes. The Part A MAC/FISS processing changes are effective January 1, 2027 and implement January 4. Some codes process systematically, while others suspend for manual review or deny. MACs may return claims Medicare cannot process and identify the reason on remittance advice, allowing correction and, where appropriate, resubmission to the primary payer or Medicare. The article does not say every returned claim will become payable.

Primary payers and Medicare report adjustments through the CAS segment of an 835 electronic remittance or paper advice. Providers must transfer CAS adjustments from the 835 unchanged to the 837 institutional claim submitted for Medicare secondary payment. MACs and their systems use the adjustment amounts and CARCs to calculate payment. Mapping software must therefore preserve the primary payer's information rather than recode an adjustment simply to force automatic processing. The January dates concern the processing change; they do not erase existing coordination-of-benefits or accurate secondary-claim requirements.

Why it matters

Incorrect adjustment mapping can distort secondary payment or cause returns. Manual-review and denial paths need ownership as well as automated-claim testing.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Coding, IT

First seen

Sep 6, 2026

Last materially changed

Sep 6, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextValidate 835-to-837 adjustment mapping and returned-claim correction routes with the MAC, including manual-review cases. Track January 1 effectiveness separately from January 4 implementation.

Permalink: #medicare-secondary-payer-adjustment-code-processing · Development ID GC-2026-0031

Noridian opens three proposed MolDX policies for comments through October 11

What changed

Noridian's August 31, 2026 Jurisdiction E notice identifies three proposed LCDs with an August 27–October 11 comment period. DL40435 concerns transcriptional biomarkers for therapeutic decision-making in renal carcinoma. DL40427 concerns next-generation sequencing for hematologic malignancies and suspected malignancies. DL40411 concerns genome-wide molecular testing for copy-number alterations and structural variants in hematologic neoplasms. The notice identifies Part B contractor jurisdictions covering northern and southern California, Hawaii/Pacific territories and Nevada. As of October 4, the comment period remained open.

The announcement links the proposals through the Medicare Coverage Database and directs commenters to identify the specific policy in each submission. Each proposal addresses a different testing question, so a laboratory's test-menu comparison and supporting evidence should be tied to the appropriate LCD. Publication for review does not make the proposed coverage criteria final or implement a current billing change. Each proposal retains its own procedural status and comment dates; shared subject matter alone does not establish that proposed criteria are final or effective.

Why it matters

Laboratories and ordering services can assess the proposed criteria while the comment opportunity remains open, without prematurely applying them as final policy.

Response type

Comment

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal, California, Hawaii, Nevada

Primary owner

Coding

Affected functions

Coding, Clinical Operations, Revenue Cycle, Compliance

First seen

Sep 6, 2026

Last materially changed

Sep 6, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextReview the actual proposed LCDs against relevant testing, identify policy-specific evidence and decide whether to comment by October 11. Keep proposed criteria separate from finalized coding and coverage changes.

Permalink: #noridian-moldx-proposed-lcds-october-comments · Development ID GC-2026-0033

CMS adjusts September plan payment user fees

What changed

CMS's August 31, 2026 MARx memo describes the September payment scheduled for September 1 and final annual user-fee adjustments. To reach the 2026 COB total of $0.65 per member, CMS raised the September collection from 7.2 to 7.4 cents after January–August collections. The MA-PD National Medicare Education Campaign collection increased from 0.021% to 0.029% for September to reach its $108.9 million annual amount. PDPs had no September NMEC assessment because their $11.4 million maximum had been reached in August. These are September-cycle adjustments, not permanent monthly rates for every future period.

The same memo places any required 2024 medical-loss-ratio remittances in the August 2026 payment, identified on the Plan Payment Report by adjustment code MLR. That separates MLR reconciliation from the September fee changes. It also explains that tickets consolidated under a parent ticket need no duplicate action from a plan already reporting the issue, and directs payment questions to the MAPD Help Desk. Plan finance should compare the correct payment month, adjustment category and applicable plan type rather than attributing every difference in a September remittance to one fee change.

Why it matters

Payment reconciliation needs plan-type exceptions and the correct month; annual fee catch-up and earlier MLR adjustments are separate items.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Finance

Affected functions

Finance, Managed Care, Compliance

First seen

Sep 6, 2026

Last materially changed

Sep 6, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextReconcile September COB and MA-PD NMEC adjustments, confirm the PDP exception and check August MLR entries separately. Investigate unresolved differences through the MAPD Help Desk without duplicating an existing consolidated ticket.

Permalink: #september-marx-plan-user-fee-adjustments · Development ID GC-2026-0045

California directs DHCS to establish Medi-Cal vision performance measures

What changed

California approved and filed AB 2756 on September 18. DHCS must establish vision-service performance measures no later than January 1, 2028 to evaluate utilization, access and availability for children and adults across fee-for-service and managed care, including specialized vision plans. Required measures include overall and per-provider utilization, annual rendering-provider counts and credentials, refractive-error diagnoses, examinations, screening tests, eyeglasses prescribed and dispensed. For eyeglasses fabricated by the California Correctional Training and Rehabilitation Authority, the measures include time between examination and receipt. Reporting uses aggregate counts and appropriate percentages with an equity framework based on available geographic and demographic factors.

The law limits calculation to existing DHCS data sources and does not require a new collection mechanism or additional data collection where a source is absent. By January 1, 2029, DHCS must post the measure list and corresponding calendar-year 2026 data, with annual performance data thereafter. An initial benchmark set is due by July 1, 2029 for use beginning in 2030 after evaluation of the initial three reporting years; plans and other stakeholders must be consulted. A separate annual complaints-and-grievances summary uses accessible existing sources and begins posting in 2029 for 2026. These are DHCS milestones, so preserving baseline data now does not imply every provider already owes a new bespoke report.

Why it matters

Reliable 2026 vision data can support later measures, but source limitations and DHCS specifications determine actual reporting rather than an assumed new collection duty.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Quality

Affected functions

Quality, Managed Care, IT, Compliance

First seen

Sep 20, 2026

Last materially changed

Sep 20, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

Long lead justification

The statute uses a 2026 baseline and directs DHCS to establish vision measures by January 1, 2028, so baseline preservation and data-gap work must begin before the ordinary 180-day horizon. (approved by Brandon Goulter, direct owner instruction executed by Codex, Oct 16, 2026)

What to do nextAssign a vision-data owner, preserve available 2026 utilization and grievance records, document data gaps and monitor DHCS measure definitions and stakeholder consultation.

Permalink: #ab-2756-medi-cal-vision-measures · Development ID GC-2026-0110

CMS releases FY 2025 SNF PEPPER reports

What changed

The September 17 MLN Connects newsletter released fiscal-year 2025 Program for Evaluating Payment Patterns Electronic Reports for skilled nursing facilities. CMS describes PEPPER as a way to review billing accuracy, spot patterns needing investigation, identify areas for monitoring or internal audit, examine possible undercoding or overcoding and track trends such as longer stays. The report is an analytical starting point for the facility’s own review. A flagged pattern alone does not establish an improper claim, repayment amount or enforcement finding.

CMS directs authorized officials, access managers and approved staff end users to obtain their organization’s report through the PEPPER Portal. A staff user signs into CMS Identity and Access with existing NPPES or PECOS credentials, requests the organization’s PEPPER business function, and needs approval from the organization’s authorized official or access manager. The Comparative Billing Report function can be requested at the same time. As of October 4, facilities can route access and review work through those controls, then assess the underlying records before deciding whether an outlier reflects clinical mix, coding or a problem requiring correction.

Why it matters

Facility-specific review can identify claims needing attention, while identity and organization approvals protect access to the report.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Coding, Clinical Operations

First seen

Sep 20, 2026

Last materially changed

Sep 20, 2026

Why it is still here

Retained for the outstanding operational assessment or implementation described below. This run does not establish comprehensive unchanged status because mandatory source coverage remains incomplete.

What to do nextConfirm authorized portal access, route the FY 2025 report to compliance and revenue cycle, prioritize meaningful outliers and document record-based conclusions and any corrective action.

Permalink: #snf-fy2025-pepper · Development ID GC-2026-0118

MACs must post quarterly Targeted Probe and Educate denial trends

What changed

CMS’s September 30 Transmittal 13971, CR 14616, requires contractors to publish quarterly Targeted Probe and Educate results on their websites, effective and implementing November 2. The business requirement calls for the top or most common denial reasons for each prioritized problem, listing three where applicable; additional reasons are encouraged if useful. CMS explains that consistent public posting across contractors responds to industry interest in these results as a tool for understanding issues and trends. The new posting obligation belongs to MACs and is not a new quarterly report imposed on providers.

The revised manual places the posting instruction beside provider-error-rate review, which considers the nature and value of the problem and the provider’s history when determining corrective action. It also preserves inclusion of claims denied for failure to respond to documentation requests in the specified error-rate calculation. Published denial patterns can inform education and sampling, but they are not a finding that every organization has the same error or requires the same corrective action. As of October 4, compliance teams can assign responsibility for reviewing relevant postings once the November instruction takes effect and assess applicability against their own records.

Why it matters

MAC trends can focus internal review, but provider-specific facts and documentation determine whether a published issue affects actual claims.

Response type

Monitor

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Compliance

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextAssign a quarterly review of relevant MAC postings, select documentation samples tied to applicable denial reasons, and distinguish observed organizational defects from general contractor trends.

1. Assign a quarterly review of California-relevant MAC TPE postings and use applicable denial reasons to select documentation samples. Compliance · due Nov 2, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #macs-must-post-quarterly-targeted-probe-and-educate-denial-trends · Development ID GC-2026-0149

Medicare premium rebate FAQ supports patient assistance

What changed

CMS’s October 3 FAQ describes a one-time $90 Medicare Improvement Fund rebate for qualifying Original Medicare Part B beneficiaries living in the United States and expressly excludes Medicare Advantage enrollees. Its eligibility and inquiry wording identifies beneficiaries who are not receiving premium assistance through Medicaid or do not pay an Income-Related Monthly Adjustment Amount. That OR wording requires an individual eligibility check through 1-800-MEDICARE before staff promise payment. The announcement concerns a beneficiary premium rebate, not a change to a provider’s payment rate or automatic authority to reduce a medical bill.

The FAQ expects most eligible recipients to receive direct deposit around October 8, followed by an email or letter, while some receive Treasury paper checks later in October. It directs eligibility inquiries to 1-800-MEDICARE and payment-status inquiries to Social Security beginning October 15. As of October 4, those delivery and status-check dates remain future expectations, not proof of payment. Patient-facing staff should use the official inquiry routes and verify the individual situation before promising a rebate or using it in a balance discussion.

Why it matters

Patient teams need to distinguish eligibility, expected delivery and actual receipt without altering medical claims on the basis of a rebate announcement.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Patient Access

Affected functions

Patient Access, Revenue Cycle

What to do nextUse the CMS FAQ and Medicare for individual eligibility questions; explain the expected delivery schedule and the October 15 start for Social Security status inquiries without promising payment or offsetting balances.

1. Use the CMS FAQ for eligibility questions and agency contacts. Do not promise eligibility or offset patient balances based solely on the rebate announcement. Patient Access · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #medicare-premium-rebate-faq-supports-patient-assistance · Development ID GC-2026-0156

CMS seeks comments on Part D data, OPO designation and home health cost-report collections

What changed

CMS’s October 1 notice submits a revision of the Part D prescription-drug-event data collection, CMS-10174, for OMB review with comments due November 2. The notice describes claims-level records supporting payment calculations, validation, quality monitoring and program oversight, including use by sponsors and related administrators. Comments are directed through the OMB thirty-day review process. As of October 4, this is a collection-review opportunity; the notice does not itself finalize a new reimbursement policy or prescribe every proposed record-layout change.

A separate September 29 sixty-day notice, with comments due November 30, seeks reinstatement without change of OPO designation and benefits-agreement forms CMS-576/576A and extension of the home-health agency cost report CMS-1728-20. The OPO forms concern designation and agreement to applicable Medicare requirements; the home-health report supports reimbursement, rates and financial analysis through its specified worksheets. These collections have different affected preparers, purposes and submission routes from the Part D notice. Organizations should match burden, clarity and automation comments to the correct identifier rather than combine the windows or characterize all three as cost-report revisions.

Why it matters

Relevant sponsors, OPOs and home-health cost-report preparers can assess reporting burden and usability before the distinct comment windows close.

Response type

Comment

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Finance

Affected functions

Finance, Managed Care, Compliance

What to do nextAssign the appropriate preparers to review each collection, supporting materials and identifier, then route any organizational comments for approval before the November 2 or November 30 deadline.

1. Assign relevant preparers to assess the collections and submit comments only through the normal organizational approval process. Finance · due Nov 2, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #cms-seeks-comments-on-part-d-event-records-and-provider-cost-report-collections · Development ID GC-2026-0157

DHCS draft outlines qualified-individual waiver pathways and safeguards

What changed

DHCS and CDSS’s joint draft ACL/BHIN dated September 25 describes approval routes allowing specified placing-agency employees or people connected to placement settings to perform qualified-individual (QI) assessments despite the usual affiliation restriction. Existing QI qualifications, training and assessment guidance are not eliminated. Under the draft, a placing-agency employee cannot assess a child for whom they are or were the caseworker or sit in the relevant casework chain of command. A behavioral health plan (BHP) employee ordinarily needs no waiver unless the specified placement-setting or placing-agency connections exist. This remains draft guidance as of October 4.

The draft’s three BHP/provider routes vary who develops or submits the request, but retain BHP signatures, independence from placement-setting influence, training, attestations and an oversight plan. They do not create unrestricted approval for placement-setting staff to assess current or potential residents: the draft restricts concurrent placement-setting employment and requires tracking of conflicts and employment changes. CDSS would issue a written decision; approval lasts one year, renewal is requested at least sixty calendar days before expiration, and denied renewal disqualifies work under that waiver until a new approval. A separate case-specific tribal route is described, and waivers cannot be shared across counties. The retained dated draft does not establish the historical public-comment deadline; verify that deadline before any submission rather than treating the draft as an issued waiver.

Why it matters

Assessment independence depends on actual casework, employment and ownership relationships, with ongoing monitoring rather than a one-time affiliation waiver alone.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

California

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Case Management, Legal

What to do nextAssess the proposed route with child-welfare and behavioral-health partners, map conflicts, qualifications and oversight responsibilities, and verify the applicable comment deadline before considering a submission. Do not treat the draft as final guidance or an approved organizational waiver.

1. Internal target: review the September 25 draft’s QI qualifications, independence, casework and employment conflicts, proposed request pathway and oversight responsibilities with operational and legal owners. Clinical Operations · due Oct 9, 2026
2. Internal target: verify the applicable public-comment deadline before any proposed submission, record the draft applicability assessment and preserve existing QI requirements pending final guidance and any actual waiver approval. Compliance · due Oct 12, 2026

Permalink: #dhcs-seeks-comment-on-qualified-individual-waiver-pathways · Development ID GC-2026-0158

RHC and FQHC claims manual aligns telehealth and deductible instructions

What changed

CMS issued September 29 Transmittal 13975, CR 14625, revising Chapter 9 telehealth and Part B deductible instructions effective October 1 with October 5 implementation. It aligns the manual with the May 27 distant-site billing instruction and expressly states there is no policy change associated with this transmittal. The revised nonbehavioral distant-site section directs individual CPT or HCPCS service codes instead of G2025 from October 1, with the appropriate revenue code and modifier 93 for audio-only or 95 for audio-video. Preventive-service cost sharing is waived without needing the former CS modifier.

The manual treats mental-health telecommunications visits separately: they are billed like in-person visits with the appropriate 93 or 95 modifier rather than G2025. It also distinguishes the originating-site facility fee, billable with revenue 0780 and Q3014, from distant-site services. Ordinary FQHC services are not subject to the Part B deductible, while the originating-site telehealth fee has the stated deductible exception; RHC deductible collection follows the manual and preventive-service exception. As of October 4, clinics should verify October coding and cost-sharing configuration before October 5 implementation rather than interpret the manual alignment as a newly created telehealth entitlement.

Why it matters

Different service contexts and clinic types produce different claim-code and deductible treatment, despite a common telehealth label.

Response type

Validate

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextValidate mental-health, nonbehavioral distant-site and originating-site workflows separately, including modifiers, preventive waivers and deductible rules, and reconcile October 5 implementation with the prior instruction.

1. Compare clinic billing templates with the updated manual and the previously issued distant-site telehealth instruction. Revenue Cycle · due Oct 5, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #rhc-and-fqhc-claims-manual-aligns-telehealth-and-deductible-instructions · Development ID GC-2026-0159

Noridian opens five proposed LCDs for comments through November 14

What changed

Noridian’s October 1 JE notice opens a comment period through November 14 for five proposed LCDs: automated brain-MRI detection and quantification DL40454, surgical nail treatment DL40462, knee osteoarthritis hyaluronic-acid injections DL40456, bacterial-presence fluorescence wound imaging DL40441 and near-infrared spectroscopy for wound and flap management DL40458. The notice identifies the applicable JE contract numbers, including California, Hawaii and the Pacific territories, and Nevada. Each topic has its own proposal and clinical scope despite the shared comment window.

Noridian directs readers to the Medicare Coverage Database for the proposed documents and asks submissions to identify the specific policy, with email and mail details on its proposed-LCD page. As of October 4, these remain proposals under review. The posting does not itself impose final restrictions, establish an effective coverage date or demonstrate that every service named will receive the same treatment. A useful organizational response should compare the relevant proposal with actual clinical evidence and workflows before making any recommendation to change current coverage or billing.

Why it matters

Affected clinical and billing owners have an opportunity to address specific evidence and operational concerns before final policy decisions.

Response type

Comment

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextAssign each relevant proposal to its service-line and billing owner, review the actual proposed criteria and route any evidence-based organizational comments before November 14.

1. Route the five policy proposals to the affected clinical and billing owners and decide whether to submit evidence before November 14. Revenue Cycle · due Nov 14, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #noridian-opens-five-proposed-lcds-for-comments-through-november-14 · Development ID GC-2026-0197

Noridian introduces secure audit file exchange through GoAnywhere

What changed

Noridian’s September 30 GoAnywhere announcement offers managed file transfer for Audit and Reimbursement documentation. Approved providers, hospitals and external partners can securely upload, download and share files with controlled folder access. Access begins by contacting the assigned auditor, who verifies the organization’s approved email domain and provides onboarding instructions. After approval requirements are met, the auditor shares a file or folder that allows the user to create and activate an account.

Certain nonprovider representatives, including consultants, third-party preparers and vendors, must submit the Medicare Cost Report Third-Party Authorization form to their auditor before access can be approved. Noridian links registration, authorization, FAQ and training resources for the platform. It expressly says GoAnywhere does not replace MCReF cost-report filing or the Noridian Medicare Portal; each application requires separate access. As of October 4, an organization should confirm the applicable audit exchange and permissions rather than assume a new transfer account satisfies a filing or portal obligation.

Why it matters

Controlled document exchange needs the right representatives and permissions, while statutory filing and other portal workflows remain separate.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks

Jurisdiction

Federal

Primary owner

Revenue Cycle

Affected functions

Revenue Cycle, Compliance, Clinical Operations

What to do nextCoordinate GoAnywhere eligibility and onboarding with the assigned auditor, complete any required third-party authorization, and validate permissions while preserving MCReF and NMP access.

1. Ask the assigned auditor about eligibility, authorize representatives and configure separate access before using the new exchange workflow. Revenue Cycle · due Oct 9, 2026
2. Record the applicability assessment and validate the affected workflow with its operational owner. This is an internal review target, not an additional statutory deadline. Compliance · due Oct 12, 2026

Permalink: #noridian-introduces-secure-audit-file-exchange-through-goanywhere · Development ID GC-2026-0198

AB 2160 directs updated Medi-Cal lactation guidance

What changed

California approved and filed AB 2160 on September 27. DHCS must issue updated lactation guidance by July 1, 2027 clarifying a continuum from lactation education and basic support through clinical consultation. The guidance must identify standard billing and reimbursement procedures and codes that reflect the covered services, and clarify managed care plans’ coverage and reimbursement responsibilities. It must also specify that lactation services are not subject to prior authorization and require neither a prescription nor referral. These are express instructions for the guidance rather than a basis to assume every claims system has already changed as of October 4.

The statute also directs plans to report how many International Board Certified Lactation Consultants are accessible in-network to members who need clinical consultation. DHCS must seek stakeholder input before issuing the guidance and may implement through letters, bulletins or similar instructions pending regulations. Implementation is conditioned on federal financial participation and necessary federal approvals. Providers and plans therefore need to follow the actual approved benefit and billing instructions while preparing for the required access, coding and network-information changes, without treating the guidance date as proof those conditions have already been satisfied.

Why it matters

Lactation access can be impaired by referral or authorization edits and unclear coding; the required guidance also makes clinical consultant availability measurable.

Response type

Monitor

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Managed Care, Revenue Cycle

What to do nextInventory lactation access edits, service codes and consultant network data. Participate in DHCS guidance review and prepare to implement the no-authorization, no-prescription and no-referral instructions when applicable conditions and guidance permit.

Permalink: #ab-2160-directs-updated-medi-cal-lactation-guidance · Development ID GC-2026-0251

SB 874 sets Medi-Cal behavioral treatment employee checks and stakeholder duties

What changed

California approved and filed SB 874 on September 27. By July 1, 2027, DHCS must ensure that each enrolled Medi-Cal entity providing reimbursed behavioral health treatment conducts, or has a third party conduct, a state and national criminal background check on employees who interact with patients. Providers must keep documentation available to DHCS on request or for a state or federal audit. This is a dated employee-check provision, distinct from the law’s separate stakeholder consideration of whether fingerprint-based checks should be required. As of October 4, teams should plan for the July milestone and confirm the implementing process rather than assume every form of fingerprint checking is already mandated.

DHCS must use existing forums for feedback on behavioral treatment coverage and billing, including assessment and reauthorization, treatment plans and outcomes, service settings, supervision, credentialing and quality-focused contracting. The guidance must remain consistent with EPSDT for people under 21. By January 1, 2029, DHCS must publish utilization data, a coverage-policy synopsis, feedback-driven changes and recommendations needed to align reimbursement with federal program-integrity requirements. Implementation is through letters, bulletins or similar instructions. The stakeholder process informs policy, while the enacted background-check and documentation provisions require a separate operational plan.

Why it matters

Behavioral treatment organizations need employee-screening evidence and audit readiness alongside participation in the agency’s policy work.

Response type

Assess

Confidence

High

Who this affects

Health systems, Provider networks, Health-tech

Jurisdiction

California

Primary owner

Clinical Operations

Affected functions

Clinical Operations, Managed Care, Revenue Cycle

Long lead justification

The chapter expressly sets July 1, 2027 for DHCS to ensure enrolled BHT entities conduct state and national checks of patient-facing employees. Advance workforce inventory, screening arrangements and audit documentation are necessary before this date beyond the ordinary 180-day horizon. (approved by Brandon Goulter, direct owner instruction executed by Codex, Oct 16, 2026)

What to do nextInventory patient-facing employees, existing state and national checks, third-party arrangements and documentation retention. Track DHCS implementation for July 1, 2027 and participate in coverage and billing forums.

Permalink: #sb-874-directs-medi-cal-behavioral-treatment-stakeholder-work · Development ID GC-2026-0252